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Abstract
Objective. Respiratory complications may persist several months into the recovery period
following COVID-19 infection. This study evaluated respiratory function and oxygen saturation
variability between young adults with a history of COVID-19 infection and controls.
Associations between cardiorespiratory function with potential biobehavioral correlates of
COVID-19 infection were also explored.
Methods. 57 adults ages 18 to 65 participated in this study (24 COVID+, 33 Control).
Spirometry was used to assess pulmonary function volumes of forced vital capacity (FVC),
forced expiratory volume in 1 second (FEV1), FEV1/FVC and peak expiratory flow (PEF).
Exhaled nitric oxide (FeNO) was measured using the NiOX VERO, a handheld electrochemical
nitric oxide analyzer and taken as a proxy of airway inflammation. Systemic inflammation
levels were assessed using salivary concentrations of inflammatory biomarkers. Oxygen
saturation variability was quantified via extended continuous oxygen saturation (SpO 2)
monitoring using linear and nonlinear analyses. Network physiology analysis was conducted to
evaluate cardiorespiratory control between SpO2, heart rate (HR), respiratory rate and skin
temperature signals measured by continuous ambulatory monitoring with an Equivital EQO 2
LifeMonitor. Physical activity levels and sedentary time were assessed using 9-day
accelerometry. COVID-19 symptom severity was assessed by participant self-report via
questionnaires.
Results. No group differences were observed for pulmonary function of FVC (COVID+:
4.22±1.01, C: 4.43±1.06 L, p=.663), FEV1 (COVID+: 3.45±0.72, C: 3.57±0.92 L, p=.865), PEF
(COVID+: 349.63±105.54, C: 373.73±140.61 L/min, p=.370), or FeNO (COVID+: 16.61±13.04,
C: 20.03±20.11 ppb, p=.285). Linear and nonlinear oxygen saturation variability did not differ

between adults with a history of COVID-19 infection and controls with no history of infection
(p>0.05). Cardiorespiratory function measured using network analysis of did not differ between
recovering COVID-19 individuals and controls (p>0.05). Sedentary time was inversely
associated with FEV1 (r=-.392, p=.040), PEF (r=-.579, p=.003), and IL-6 concentrations (r=.370, p=.049). COVID-19 disease severity was inversely associated with FVC (r=-.461, p=.012)
and FEV1 (r=-.365, p=.040). Number of symptoms was inversely associated with FVC (r=-.404,
p=.025).
Conclusions. Pulmonary function, inflammation levels and oxygen saturation variability were
similar between individuals with a history of COVID-19 infection and controls without a history
of COVID-19 infection. Network interactions between regulatory components of the
cardiorespiratory system were also similar between recovering COVID-19 individuals and
controls. Findings suggest that cardiorespiratory function and dynamic control of SpO 2 may not
be impaired following COVID-19 infection in young adults. Moreover, increased sedentary time
and disease severity may have negative effects on pulmonary function in individuals recovering
from COVID-19.
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Glossary of terms
Abbreviation
FeNO
SpO2
HR
COVID-19
SARS-CoV
MERS-CoV
ACE2
ARDS
FVC
FEV1
PEF
TNF-α
DLCO
IL
CRP
COPD
SD
RMS
MSE
DFA
SEM
ECG
SaO2

Term
Fractional concentration of exhaled nitric oxide (ppb)
Oxygen saturation (%)
Heart rate (bpm)
Coronavirus of 2019
Severe acute respiratory syndrome coronavirus
Middle East respiratory syndrome coronavirus
Angiotensin Converting Enzyme 2
Acute respiratory distress syndrome
Forced vital capacity (L)
Forced expiratory volume in 1 second (L)
Peak expiratory flow (L/min)
Tumor necrosis factor
Diffusion limitation carbon monoxide
Interleukin
C-reactive protein
Chronic obstructive pulmonary disease
Standard deviation
Root mean square
Multiscale entropy
Detrended fluctuation analysis
Sensor electronics module
Electrocardiogram
Arterial oxygen saturation (%)
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Chapter 1: Introduction
The World Health Organization declared the novel coronavirus disease of 2019 (COVID19) a global pandemic in March of 2020. Since its onset, there have been over 30.5 million cases
reported globally, with case reports increasing every day. The United States is ranked number
one in cases at over 46.25 million confirmed cases to date.1 As time progresses, the number of
people recovering from COVID-19 increases as well. As we continue to study the epidemiology
of the virus in regard to its onset and spread, a focus in research has shifted towards
understanding the long-term health effects of COVID-19 on survivors.
The lungs are the organ most affected by COVID-19 and act as a major point of viral
entry into the body. The novel strain of coronavirus is caused by SARS-CoV-2 infection, a
member of the Coronaviridae family that also encompasses severe acute respiratory syndrome
coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV).
The spike (S) protein of SARS-CoV-2 has a significant binding affinity for the Angiotensin
Converting Enzyme 2 (ACE2) receptor that is prevalent in type 2 alveolar epithelial cells of the
human lung.2 ACE2 receptors are also widely distributed outside of the lung, including the
heart, kidneys, vasculature, brain and gastrointestinal tract. These ACE2 receptors are sites for
viral replication and spread, leaving these organs at high risk for infection.2
Viral replication inside the cell causes cellular pyroptosis, a highly inflammatory cell
death via infection, which causes the release of damage pattern molecules. Nearby epithelial
cells and alveolar macrophages recognize the release of damage pattern molecules and release
pro-inflammatory cytokines in response. This cytokine release evokes an immune response via
monocytes, macrophages and T cells that continue this pro-inflammatory feedback loop. In
some patients, a large and nonspecific immune response to cell damage becomes dysregulated

1

and there is an over-production of these cytokines. This cytokine release can spread systemically
in a “cytokine storm” through the circulation, leading to multi-organ damage.3 Increased
systemic inflammation levels are associated with worsened COVID-19 infection disease severity
and therefore degree of cardiorespiratory injury during acute infection. More specifically
however, this dysregulated inflammatory response leads to alveolar damage and acute injury to
both the lung and its microvasculature. This causes the alveoli and the lungs to fill with blood
and plasma fluid rather than air, limiting diffusion capacity and causing respiratory distress.4
This fluid buildup can lead to pneumonia and in more severe cases, acute respiratory distress
syndrome (ARDS). In addition to a prolonged inflammatory state, the exacerbated infections
that result from COVID-19 and its subsequent respiratory diseases leads to impaired diffusion
capacity and gas exchange resulting in persistent hypoxemia.5–7 The oxygen deficit as well as
the acute injury to the lung also manifests as a diminished overall lung capacity.
The potential sequalae associated with COVID-19 infection can be derived from the
acute infection caused by SARS-CoV-2 as well as extrapolated from previous follow-up data
associated with SARS-CoV and MERS-CoV survivors.6,8,9 COVID-19 infection targets the
lower respiratory tract, primarily the alveoli of the lungs and its surrounding infrastructure. In
moderate to severe cases, the infection causes the development of pneumonia and ARDS,
resulting in consolidation of the lung and increased difficulty breathing. These secondary
conditions associated with COVID-19 infection concurrent with a heightened inflammatory state
cause lasting damage to the alveoli, the pulmonary microvasculature and the lobes of the lung,
resulting in scarring and are indicated in the pathogenesis of pulmonary fibrosis.8,10–13 Further
persisting injury and potential fibrogenesis could result in those COVID-19 survivors that
required mechanical ventilation during the infection period, exacerbating the existing injury to
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the lower respiratory tract 8,11 and causing atrophy of the respiratory muscles.14 During the
infection period, the body’s vasculature including the microvessels of the lung exist in a
procoagulant state, indicating high risk for future occlusions.9,10 These structural changes to the
lung present as functional changes to the respiratory system primarily including diminished gas
exchange and general difficulty breathing. These deficiencies result in persisting symptomology
from the infection period to recovery including hypoxemia, dyspnea, cough and fatigue.5,10,15
Similar to the sequalae reported in SARS-CoV and MERS-CoV infections,8,9,12 data published
on recovering COVID-19 individuals suggests that these pulmonary abnormalities can persist
several months into the recovery period.8,11–13,16 Standard pulmonary function testing can give
insight into these changes in general lung function, strength of respiratory muscles and airway
obstruction from inflammation or swelling.17
A nonconventional approach to assessing airway inflammation that is now being
explored in COVID-19 patients is measurement of exhaled nitric oxide. Widely utilized with
asthma patients, exhaled nitric oxide gives indication to airway-specific swelling related to
inflammation. During pro-inflammatory states such as COVID-19, cytokines stimulate the
overproduction of nitric oxide in an attempt to combat reductions in airway caliber due to
swelling. The preliminary use of this testing has been both as a supplementary diagnostic tool
during active infection as well as a means of evaluating airway inflammation during recovery
post-infection. Due to the novelty of exhaled nitric oxide testing in the COVID-19 population,
utilization of this measure in the current study will provide insight into a potentially useful
clinical indicator directly related to COVID-19 infection that may contribute to ongoing
symptomology and respiratory limitation experienced post-infection.
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Persisting hypoxemia is one of the most common symptoms during COVID-19 infection
and is associated with COVID-19 mortality.5 While standard intermittent pulse oximetry is
beneficial in classifying a hypoxemic state, continuous sampling is more intuitive when studying
respiratory function. Oxygen saturation variability can be derived from continuous pulse
oximetry measurement, measured both individually and in conjunction with other
cardiorespiratory signals in a network approach, and gives holistic insight into physiological
control of the oxygenation process as well as the integrity of the cardiorespiratory system.18
Variability can be defined using traditional linear metrics such as mean and standard deviation
(SD) but also quantified using novel nonlinear methods.
Measurement of oxygen saturation variability via nonlinear methodology provides a
novel view of hypoxemia, one of the most predictive indicators of COVID-19 infection, allowing
a better understanding of the oxygen homeostasis process and the lung injury that may be
responsible for its malfunction. SpO2 as a physiological signal is constantly changing and
adapting to overcome stressors and maintain a desired physiological state (normoxia), observed
as variability. Linear methods, such as the SD of values around the mean SpO2, fail to account
for these natural fluctuations, and therefore only provide minimal insight into the complex
dynamics exhibited by SpO2. Assessing variability from a nonlinear perspective helps
researchers successfully capture and define these natural fluctuations in SpO2 and therefore more
accurately identify exacerbations and hypoxemia in clinical populations, such as those
recovering from COVID-19 infection. Nonlinear variability analysis has been extensively
studied in other physiological signals such as HR, where reductions of variability are indicative
of aging and disease.19,20 Injuries to gas exchange efficiency observed during COVID-19
infection may be indicated by similar reductions in variability.
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The cardiorespiratory system as a whole is composed of several regulatory components
that work together to maintain proper cardiorespiratory function. These components (e.g., the
brain and neural circuitry, heart, lungs, circulation, skeletal muscle in the form of the diaphragm)
are “coupled” to create an integrated physiological network that is in constant communication
using information signaling. Signal outputs generated by these organ systems include heart rate,
respiratory rate, skin temperate and oxygen saturation. Network analysis can be used to measure
the regulatory signaling between components, and assesses a system’s ability to maintain a
desired physiological state by adapting to the physiological and pathological stressors placed
upon it. Reductions in signaling between components (i.e., systems/signal isolation) is indicative
of injury to the system, and occurs in pathology.21–23 Therefore, network analysis of SpO2
homeostasis as it relates to other cardiorespiratory signals allows researchers to identify any
points of isolation or injury amongst regulatory components of the cardiorespiratory system
sustained during COVID-19 infection that may contribute to decreased control of SpO2.
Integration between these signals can further indicate the degree of control one component has
on the maintenance of the other (i.e. how much other cardiorespiratory components such as HR
contribute to SpO2 homeostasis), and vice versa. Injuries sustained during COVID-19 infection
may result in persisting cardiorespiratory injury that decreases the system’s ability to adapt to the
stressors placed upon it. This isolation amongst system components can lead to overall
dysfunction (i.e. hypoxemia) seen as system uncoupling. These measures work in unison with
standard pulmonary function testing and exhaled nitric oxide to give a comprehensive view of an
individual’s global cardiorespiratory function and can be used to assess recovery status and
progression.
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There are many biobehavioral factors that may favorably or detrimentally modulate
cardiorespiratory function. Physical activity levels and amount of sedentary time are two notable
contributors to cardiorespiratory outcomes. Adequate physical activity levels can be protective
for cardiorespiratory function as they have been shown to promote proper pulmonary function
and reduce systemic inflammation levels.24–28 Conversely, lower levels of physical activity are
associated with increased respiratory symptomology and general disease severity in clinical
populations including increased frequencies of exacerbations, gas exchange impairments and
elevated inflammatory profiles.29–33 Similarly, sedentary time may cause a detraining effect on
the lungs, including reduction in strength of respiratory muscles and reductions in pulmonary
function.34–36 Increased sedentary time has also been associated with elevated inflammatory
profiles in several populations.37–39 With decreased access to physical activity opportunities with
COVID-related restrictions such as quarantine, individuals who have experienced COVID-19
infection may not experience the protective effects of adequate physical activity and suffer from
the detraining associated with increased sedentary behaviors. Whether physical activity and
sedentary behavior are associated with cardiorespiratory function in a setting of COVID-19
recovery has not been specifically explored.
In summary, measures of respiratory function are predictors of COVID-19 mortality5 and
offer insight into disease severity, progression and recovery. Additionally, these indicators may
be used to assess survivor’s susceptibility for future respiratory decline as they may be at
increased risk for other respiratory conditions due to ongoing inflammation and injury. The
proposed relationship between SARS-CoV-2 infection and its long-term implications are
depicted in Figure 1. Furthermore, studies utilizing antibody testing reveal that immunoglobulin
G antibodies for COVID-19 can dissipate as early as three months after disease recovery,
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indicating that these survivors are at risk for repeated COVID-19 infection.13 Lastly, assessment
of prolonged effects of COVID-19 can give insight into rehabilitation needs for these
individuals. Continuous SpO2 monitoring and network analysis of SpO2 can provide novel
insight into components of cardiorespiratory control that contribute to fluctuations in oxygen
saturation variability and subsequent cardiorespiratory uncoupling. General assessments of
recovering patients are limited during the infection/hospitalization period with fear of virus
transmission and lack of resources. The use of at-home testing can eliminate these concerns and
allow direct measurement of multiple aspects of lung function. This modality also is beneficial
in a follow-up setting, allowing for access to more subjects than with hospital visits alone.
Figure 1. Events From Onset of Infection to Long-Term Respiratory Implications

Progression of acute injuries from SARS-CoV-2 viral entry and replication through development of potential
future respiratory risk.

Therefore the purpose of this study was 1) to compare pulmonary function, airway
inflammation and oxygen saturation variability between individuals with a history of COVID-19
infection and controls with no history of COVID-19 infection using portable pulmonary function
testing and extended continuous SpO2 monitoring, respectively, 2) to understand and compare
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exchange of information between regulatory components of the cardiorespiratory system in
individuals with a history of COVID-19 infection and controls as measure of dynamic
cardiorespiratory control using network analysis of SpO2, HR, respiratory rate and skin
temperature signals, and 3) to explore systemic inflammation, physical activity levels, sedentary
time and COVID-19 disease severity as potential biobehavioral correlates of cardiorespiratory
function in individuals recovering from COVID-19 infection. It was expected that 1) individuals
with a history of COVID-19 will have reduced respiratory function (decreased pulmonary
function and increased airway inflammation), and decreased oxygen saturation variability
compared to controls suggesting individuals with a history of COVID-19 will have decreased
dynamic cardiorespiratory function, 2) there will be decreased information signaling between
SpO2, HR, respiratory rate and skin temperature signals in recovering COVID-19 individuals
suggesting isolation within regulatory components of the cardiorespiratory system (i.e., loss of
integrated cardiorespiratory control) and 3) that increased systemic inflammation, decreased
physical activity, increased sedentary time and increased disease severity will be associated with
decreased cardiorespiratory function in recovering COVID-19 individuals. The proposed
measures to evaluate the long-term implications of SARS-CoV-2 infection are shown in Figure
2.
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Figure 2. Proposed Measures to Evaluate Cardiorespiratory Function following SARSCoV-2 Infection

Summary of three respiratory sequelae assessed and their associated methodologies.
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Chapter 2: Literature Review
The following literature review will introduce concepts related to 1) the pathophysiology
of COVID-19 caused by SARS-CoV-2 infection, its clinical manifestations and potential
sequelae; and 2) the existing uses and implications of the methodology to be used to assess
respiratory function in COVID-19 survivors (Figures 1 and 2). This review provides rationale
for a study to explore the potential long-term cardiorespiratory implications associated with
COVID-19 infection including measures of pulmonary function, inflammation, and gas exchange
in survivors. This review seeks to illustrate the current knowledge provided in the existing
literature regarding the largely unknown lasting effects of COVID-19 infection. This study seeks
to determine whether there is diminished respiratory function in COVID-19 survivors when
compared to those with no history of COVID-19.

SARS-CoV-2 Infection Pathophysiology
On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic.40
This novel strain of coronavirus is caused my SARS-CoV-2 infection, a member of the
Coronaviridae family that also encompasses SARS-CoV and MERS-CoV.4,7,40 The SARS-CoV2 pathogen enters the body through respiratory droplets via receptor-mediated endocytosis,3,7,40
targeting primarily the lower respiratory tract.3,4,40 The spike (S) protein of SARS-CoV-2 has a
significant binding affinity for the ACE2 receptor that is prevalent in type 2 alveolar epithelial
cells of the human lung.3,4,12,41 While most abundant at these type 2 pneumocytes, ACE2
receptors are also widely distributed in extrapulmonary organs including the heart, kidneys,
vasculature, brain and gastrointestinal tract.2 Viral replication inside these cells causes cellular
pyroptosis, a highly inflammatory cell death via infection, causing the release of damage pattern
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molecules. Type 2 alveolar epithelial cells and macrophages recognize this pattern release using
pattern-recognition receptors and respond with a local inflammatory response.3 This process of
cytokine release prompts surrounding pneumocytes to recruit immune cells such as monocytes,
macrophages and T cells to the site of inflammation, creating a pro-inflammatory feedback
loop.3,12,42 In some patients, a large and nonspecific immune response to cell damage becomes
dysregulated and there is an overproduction of cytokines. This cytokine release can spread
systemically in a “cytokine storm” leading to multi-organ damage.3,7,42 More specifically,
however, this dysregulated immune response leads to diffuse alveolar damage and acute injury to
both the lung and its microvasculature.3,6,43,44 Diffuse alveolar damage, as defined by
Katzenstein and colleagues (1976), is a nonspecific reaction of the lung to pathogens and other
harmful agents, resulting in both alveolar and endothelial injury.45 The injury causes
desquamation of type 2 alveolar cells, resulting in fluid and cellular exudation, limiting diffusion
capacity and causing respiratory distress.3,4,11,42–44,46,47

Clinical Respiratory Manifestations of COVID-19
Viral infection and replication cause injury to the lung’s infrastructure and microvasculature,
resulting in impaired functionality. Respiratory distress caused by COVID-19 can be attributed
to a wide range of symptomology, extending from mild to life-threatening respiratory indicators.
The aforementioned vascular leakage that occurs at the alveolar epithelium causes abnormal gas
exchange and inefficient oxygenation of the blood. This is clinically seen as a low blood oxygen
SpO2, defined as hypoxemia at values below 95%.5,40 In mild to moderate cases, decreased SpO2
levels combined with pulmonary inflammation manifest as common respiratory symptoms
including cough, dyspnea, and fatigue. Additionally, COVID-19 infection causes an aggressive
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form of pneumonia4,7,10,40,42,44 that can lead to exacerbated alveolar damage and in more severe
cases, the development of ARDS.2,3,8,10 These secondary respiratory conditions are often
identified from radiological abnormalities, most commonly seen as pneumonia, hyaline
membrane formation, lesions, pulmonary consolidation, and pure or mixed ground glass
opacities.4,6,7,9,12,13,40,42,43,47 Patients with persisting hypoxemia or severe secondary infection (i.e.
ARDS) may require supplementary oxygen and in some cases mechanical ventilation due to
respiratory failure. A study conducted by Wang et al. studying 36 COVID-19 cases requiring
admittance to the intensive care unit reported that approximately 89% of patients could not
breathe spontaneously and required some form of oxygen supplementation or mechanical
ventilation.48 In summary, the acute lung injury caused by COVID-19 infection manifests most
commonly as hypoxemic respiratory distress and its associated symptomology, anatomical
alterations seen by radiological scans and the development of secondary respiratory infections.
This symptomology may persist long after the infection period and gives insight into potential
long-term complications that may arise for these survivors.
Concurrent with respiratory symptomology, the heightened systemic state of
inflammation during COVID-19 infection, termed the “cytokine storm,” has earned a critical
rapport in clinical assessment of COVID-19 individuals. The cytokine storm described in
COVID-19 patients was previously defined by researchers as “an activation of auto-amplifying
cytokine production due to an unregulated host immune response.49 The positive inflammatory
feedback loop between immune cells and inflammatory molecules has lasting implications for
immune function in the host. High levels of cytokines lead to the overactivation of lymphocytes,
specifically T cells. T cell exhaustion results in amplified levels of inflammatory molecules such
as interleukin-6 (IL-6) and tumor necrosis factor (TNF-α) that play a role in lymphocyte
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necrosis.42 With this, lymphopenia has been observed in COVID-19 patients and leaves them at
higher risk for further inflammation as well as increased susceptibility for future infection. 3,40,42
Furthermore, as this hyperinflammation affects the host in a systemic fashion, respiratory
function can be indirectly affected by extrapulmonary factors including ongoing cardiac and
vascular injury.6 Finally, the body’s vasculature, including the microvessels of the lung, exist in
a procoagulant state after infection, indicating high risk for future occlusions.9,10 These findings
indicate that chronic inflammation due to COVID-19 infection results in overactivation of the
immune system, ultimately resulting in lymphopenia and increased susceptibility for future
respiratory decline.

Potential Sequelae of COVID-19
As the novelty of the COVID-19 pandemic recedes, the population of recovered cases that can
and have been accessed to evaluate the long-term physiological implications of COVID-19
infection on survivors becomes increasingly available. To date, much of the potential sequelae
associated with COVID-19 can be derived from both the acute infection caused by SARS-CoV-2
as well as extrapolated from previous follow-up data associated with SARS-CoV and MERSCoV survivors,6,8,9 and from individuals recovering from the secondary respiratory conditions
that may develop during COVID-19 infection, such as ARDS.43 The secondary infections
associated with COVID-19 paired with a heightened inflammatory state cause lasting damage to
the alveoli, the pulmonary microvasculature, the lobes of the lung, and the airway. In more
critical cases, injuries may result in scarring and are indicated in the pathogenesis of pulmonary
fibrosis.8,11–13 Pulmonary fibrosis is associated with chronic inflammation during fibrogenesis 50
and restricted ventilation and diffusion capacity as a result.51 A study investigating the

13

progression of radiological abnormalities one month after discharge in COVID-19 patients found
despite the gradual resolution of parenchymal findings (i.e. ground glass opacities), 39% of
participants still displayed residual fibrosis.13 Further persisting injury and potential fibrogenesis
could result in COVID-19 patients that require mechanical ventilation8,11 and cause atrophy of
the respiratory muscles.14,52 A study conducted by Levine and associates (2008) showed that
patients who underwent mechanical ventilation who had diaphragmatic inactivity exhibited a
more than 50% decrease in muscle cross-sectional area in as little as 18 hours.53 Mechanical
ventilation is also associated with barotrauma and the development of lesions that may lead to
edema.54 Taken together these findings suggest that COVID-19 survivors, especially those with
more severe infection experiences (e.g. development of ARDS, ventilation requirement), are at
increased risk for lasting respiratory complications following infection including fibrosis and
mechanical ventilation injury.
Existing follow-up data suggests that the pulmonary abnormalities seen during COVID19 infection can persist several months into the recovery period.8,11–13,16 These deficiencies
result in persisting symptomology from infection to recovery including hypoxemia, dyspnea,
cough and fatigue.10 A study conducted with 110 discharged COVID-19 patients of varying
disease severity tested pulmonary function three months after hospital release. Diffusion
abnormalities were observed in 47.2% of cases (DLCO) followed by diminished total lung
capacity in 25% of subjects.6 These findings were consistent with that of gas exchange
efficiency measured as diffusion limitation of carbon monoxide (DLCO) and total lung capacity
measurement in SARS-CoV survivors at 0.5-2 years follow-up55–57 and DLCO measurement
alone at 12 months follow-up of MERS-CoV subjects.58 Another study of 55 recovered COVID19 patients conducted at three months post-discharge revealed pulmonary function anomalies in
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25.45% of subjects as well as radiological abnormalities in 74.55% of survivors. This same
study also conducted immunoglobulin G serum antibody testing and found that 14.55% of their
cohort tested negative, suggesting that these individuals are susceptible to repeat infection as
early as three months after recovery.12 Despite the growing number of follow-up studies, if and
when COVID-19 survivors will return to normal respiratory function and fully recover from the
effects of the virus still remains largely unknown. A previous study looking at SARS-CoV
survivors reported respiratory abnormalities up to 15 years post-infection, including diminished
diffusion capacity in 38.46% and impaired mid-flow maximum expiration (expiratory flow) in
40.38% of patients.41 Likewise, long-term studies of ARDS patients revealed persistent
reduction in health-related quality of life up to five years after hospital discharge,59,60 correlating
with pulmonary dysfunction in these subjects.61 Overall, current follow-up studies assessing
respiratory function in COVID-19 survivors resemble that of existing data of individuals
recovering from similar respiratory infections; reporting impaired gas exchange, radiological
abnormalities and diminished total lung capacity. Consequently, measures of respiratory
function may be valuable predictors of COVID-19 infection severity and symptomology, and
therefore disease progression and recovery.

Salivary Inflammatory Biomarkers
The systemic dysregulated inflammatory response known as the cytokine storm is indicative of
not only the presence of COVID-19 infection, but also can be used for stratification of COVID19 disease severity.3,62 These findings are consistent with the relationship between inflammatory
biomarkers and disease severity and outcomes seen in MERS-CoV, SARS-CoV and chronic
obstructive pulmonary disease (COPD) patients.62,63 Researchers have found elevated plasma
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levels of chemokines, interleukins (IL) 2, 6, 8, 10 and 1ß, C-reactive protein (CRP), TNF-α and
D-Dimer in COVID-19 patients,7,40,62 with higher levels being indicative of more severe
infection. These biomarkers of inflammation can be measured in saliva as a proxy for serum
concentrations.62 While serum levels are representative of systemic inflammation, relationships
between inflammatory biomarkers and pulmonary injury have been identified. Elevated
inflammatory markers, specifically CRP, were found to be associated with severity of
hypoxemia5 and therefore degree of injury in COVID-19 patients. Similar indicators were
shown in a three-month follow-up study where COVID-19 survivors with abnormal computed
tomography findings had significantly higher CRP concentrations.12 This relationship between
CRP levels and pulmonary function has previously been reported in patients with COPD as
higher CRP concentrations were correlated with decrease lung volumes.64 Furthermore, IL-1ß
has been found to play a strong role in fibrogenesis at the lung65 while TNF-α has been indirectly
associated with the development of pulmonary edema as it contributes to alveolar membrane
permeability.66 Moreover, augmented levels of interleukins 6 and 8 have been found as
predictive of poor outcomes in acute lung injury patients.66,67 More specifically, IL-8 is
responsible for upregulation of adhesion molecules66 as well as functions in altering the integrity
of the alveolar membrane.67 The remainder of these biomarkers are also responsible for the
recruitment of additional inflammatory cells including cytokine and chemokine production and
neutrophil and macrophage activation.42,66 A comprehensive overview of these biomarkers and
their inflammatory functions as they relate to respiratory injury can be seen in Table 1. Because
these biomarkers are indicative of injury, they may be helpful in identifying recovery progress in
survivors.
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Table 1. Inflammatory Biomarker Functions
IL-6

Predictive of poor outcomes in ALI,
inflammatory cell recruitment

IL-8

Predictive of poor outcomes in ALI,
upregulates adhesion molecules, alveolar
membrane permeability, inflammatory cell
recruitment

IL-1ß

Role in pulmonary fibrogenesis,
inflammatory cell recruitment

CRP

Associated with decreased lung volumes &
severity of hypoxemia, abnormal CT findings,
inflammatory cell recruitment

TNF-α

Affects alveolar membrane permeability,
contributes to pulmonary edema,
inflammatory cell recruitment

IL, interleukin; ALI, acute lung injury; CRP, C-reactive protein; CT, computed tomography; TNF-α, tumor
necrosis factor

Pulmonary Function Testing
As previously discussed, current follow-up data on COVID-19 survivors suggests that impaired
lung function may extend several months into the recovery period.6,12 Pulmonary function
testing can give insight into general lung capacity, strength of respiratory muscles and airway
obstruction from inflammation or swelling.17 Standard pulmonary function testing utilizes a
single spirometry maneuver to capture multiple determinants of pulmonary function including
forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and peak expiratory
flow (PEF).17,68 This manuever is repeated for three trials, and the best score for each pulmonary
function volume is taken as a final measure of function. Spirometry is commonly used in
clinical practice to assess lung impairment and disease progression in populations with
respiratory conditions such as asthma and COPD.68–70 Individual predicted values are
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determined by subject age, height, sex and ethnicity68,71 as pulmonary function scores are often
reported in percentage of predicted value.17,68–71 FVC is clinically defined as the total volume of
air that can be exhaled during a forced, maximal expiration effort following complete inflation of
the lungs.69 Attenuated FVC values are common in restrictive lung diseases such as idiopathic
pulmonary fibrosis.70 FEV1 refers to the amount of air that can be forcibly expired in 1 second
following maximal inhalation.69,70 Reduction is FEV1 values indicates increased airway
resistance to expiratory flow70 and is common in obstructive lung diseases.70,72 Individual FVC
and FEV1 values of greater than or equal to 80% are considered normal17,69 and these values
have been found to be independently associated with mortality in asymptomatic (without
obstructive disease) individuals.73 Additionally, disease severity can be classified by the degree
of deficiency (how far a score is below 80%) seen in FEV1 scores.68 A ratio of FEV1/FVC can
be used to distinguish types of lung disease or impairment69,70 however it must be analyzed in
conjunction with individual FEV1 and FVC values.74 A normal FEV1/FVC ratio has been
defined as greater than or equal to 70%. A more pronounced reduction in one value compared to
another affects the ratio and can be indicative of types of lung disease as mentioned.70 However,
if both values are reduced to the same extent, the ratio is technically preserved. Despite this
presumably normal ratio, this pattern is associated with decreased functional capacity and
increased mortality.74 PEF is a measure of maximum flow achieved during a forced expiration
effort following maximal inflation of the lungs. PEF measurement is indicative of lung volume,
strength of expiratory muscles, airway caliber and elastic recoil capacity of the lung, where
diminished PEF is indicative of airflow obstruction and deficiency in one or more of these
areas.17 According to the British Lung Foundation and American Lung Association, normal PEF
scores in adults range from 400 to 700 L/min, or 80% or higher of predicted values for
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participant demographic.71,75 Additional considerations (and potential limitation) regarding these
measurements are that they are all contingent on subject effort.70 Therefore, proper technique,
instruction and participant motivation are necessary for accurate data collection.68,70
Decreased pulmonary function values have been reported in both COVID-19 survivors
and in survivors of other respiratory disease. A three-month follow-up study conducted with
COVID-19 patients revealed 25% of participants showed pulmonary function deficiency with
approximately half of them showing reduced FVC or FEV1 values.12 Similar reports were
published in COVID-19 patients with abnormally low FEV1 and FVC values at 6 weeks followup76 and at the time of patient discharge.6 This is consistent with findings of COPD patients
showing reduction in both FEV1 and FVC scores independent of markers of inflammation.63
PEF has also been found to show greater decline in more severe COPD patients, indicating
disease progression.77 Furthermore, a study of ARDS survivors at an average of 30-months postdischarge revealed that 56.3% of subjects displayed an obstructive pattern, restrictive pattern, or
combination of the two.78 These findings indicate that pulmonary function should be utilized to
assess COVID-19 patients and identify restrictive flow patterns.76 The current study will identify
if pulmonary dysfunction persists in young adults with a history of infection, and therefore
provide indication if this population should be monitored during the recovery period and whether
or not these individuals may require therapeutic intervention post-infection.

Exhaled Nitric Oxide
Ongoing inflammation from COVID-19 infection can be measured systemically in the
circulation or saliva, but also can be assessed specifically to the airway. Airway inflammation
can be measured as concentrations of nitric oxide and may act as a partial source of pulmonary
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dysfunction as it affects expiratory flow measures by obstructing the airway. Fractional nitric
oxide in exhaled breath, or exhaled nitric oxide (FeNO), measurement is commonly used in
patients with respiratory disease79–81 but has been only preliminarily used with COVID-19
patients.82–86 FeNO is an indicator of airway caliber and inflammation as nitric oxide is essential
in regulating vasomotor tone in the pulmonary circulation80,87 and has previously been associated
with changes in lung function.79 Aside from its role in broncho- and vasodilation, nitric oxide
has also been identified in immune function as it can damage pathogens and recruit T-helper
cells to produce antibodies.81 Under inflammatory conditions, several cytokines that are
prevalent in COVID-19 (i.e. IL-1ß, TNF-α, etc.) stimulate the overproduction of nitric oxide in
order to combat the change in airway size due to adjustments in vascular tone.80 Higher
concentrations of nitric oxide in expired breath represent increased levels of inflammation in the
airway and airway caliber reduction.79,80 Reference FeNO values are dependent on subject age,
sex, anthropometrics, smoking status and dietary habits.81
A study conducted on 49 intensive care patients found that exhaled NO values in
critically ill patients with pneumonia were elevated compared to those without. This study also
found that FeNO values were independent of systemic NO levels, indicating that FeNO values
were specific to airway inflammation.80 These findings were echoed in a recently published
study that used FeNO as a rapid screening tool for COVID-19 patients, where it successfully
identified 88% of infected subjects.83 Similarly, Yang and colleagues also applied this modality
for COVID-19 diagnostic use. Results of this study were consistent with previous findings and
found that FeNO levels were significantly higher in COVID-19 patients compared to healthy
controls. It is important, however, to complete additional testing as patients with other chronic
diseases (asthma, COPD, etc.) will be classified similarly to COVID-19 subjects in this
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assessment.82 Few studies have evaluated FeNO levels in recovered COVID-19 individuals and
have yielded mixed findings.84–86 Thus, FeNO measurement may be a useful modality in
complementing other forms of respiratory evaluation such as pulmonary function testing
however more data is necessary to understand its true significance as a measure of respiratory
recovery post-infection.

Oxygen Saturation
Diminished lung capacity and functionality due to the acute lung injury caused during infection
are largely attributed to reductions in diffusion capacity due to diffuse alveolar damage. The
efficiency of gas exchange at the lungs is therefore compromised, and oxygen cannot reach and
bind to the red blood cells that pass by in the circulation. This efficiency can be measured as
SpO2, and can fluctuate throughout the day based on a number of things, including ambient
oxygen, activity levels, and general lung health. Desaturations due to pathology in the lung can
be classified as exacerbations and result in bouts of hypoxemia or low blood SpO2 levels. These
changes in blood oxygen levels can be monitored closely and give important insight into
functionality of not only the lung but the entire cardiorespiratory system. While spot check SpO2
is considered the fifth vital sign, continuous monitoring may be a more effective way of
evaluating these fluctuations.
SpO2 is a measure of the percentage of hemoglobin binding sites that are occupied by
oxygen molecules relative to how many hemoglobin binding sites there are total. Each
hemoglobin is able to carry four oxygen molecules for transport to the rest of the body.88
Denoted as a percentage, normal saturation values for a healthy individual at sea level range
between 96% and 98%.89 Persistent hypoxemia is one of the major symptoms associated with
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COVID-19, and hypoxemia has been found to be independently associated with in-hospital
mortality in COVID-19 patients.5 SpO2 measurement has also been shown to be predictive of
acute exacerbations in diseased individuals90 and displayed a high negative predictive value (9294%) for predicting severe illness in children.91 Clinically, hypoxemia is defined as an SpO2
below 95%,18,92 and severe hypoxemia is defined as an SpO2 value below 90%.5,40 Patients
experiencing severe hypoxemia require some form of oxygen therapy through supplementation
or mechanical ventilation in cases of hypoxemic respiratory failure.92 Oxygen concentrations in
the blood are determined by a variety of factors, including ventilation and gas exchange, as
specific to the lung.89 As previously mentioned, SARS-CoV-2 viral infection and replication in
alveolar epithelial cells causes excessive inflammation and acute lung injury, causing fluid
exudation into the lung. The most prevalent of these injuries is diffuse alveolar damage, which
directly damages the alveolar blood gas barrier at the lung where gas exchange occurs. The
potentiated inflammation in this area also damages the pulmonary microvasculature, which
includes the alveolar capillaries that transport blood adjacent to the alveoli to allow for
oxygenation to occur.3,6,43,44 This causes limited gas exchange capabilities, which is why oxygen
levels in the blood fall below normal.
Spot check pulse oximetry is a standard noninvasive method for measuring oxygen
concentration which uses light wavelengths to determine the ratio of oxygenated hemoglobin,
providing an instant SpO2 value for that given point in time.88 While this is the clinical standard
for SpO2 measurement, continuous measurement of SpO2 gives more extensive saturation data to
analyze than intermittent collection93,94 and spot check measurement fails to differentiate
between natural fluctuations and acute exacerbations of SpO2.94 Oxygen saturation variability
can be defined as the complex pattern of SpO2 fluctuations93 and gives insight into physiological
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control of the oxygenation process as well as the integrity of the cardiorespiratory system.
Variability analysis can be conducted using both linear and nonlinear methods. Linear analysis
consists of basic variability measures such as mean, SD, root mean square (RMS), range, and
average hourly change. Nonlinear variability analysis attempts to capture the true pattern of
SpO2 fluctuations through measurement of pattern regularity, complexity and self-similarity.18,95

Oxygen Saturation Variability and Complexity
In the field of physiology across all types of biological signals, the concept of homeostasis, or a
state of equilibrium, is thought to be the overall goal for an organism and its many systems.
However, the most basic understanding of homeostasis suggests that the human body is
constantly stable, or at least in a “steady” state. Research has repeatedly demonstrated, however,
that the human body is changing physiological states constantly- rest to wake, stress to
relaxation, experiencing a wide range of emotions, and continuously adapting to changes to their
environment and the stressors placed upon it (i.e. cold weather, exercise). Therefore, the systems
use signaling, or regulatory information exchanged between the structural units of a system to
elicit a physiological response, usually to maintain/return to a homeostatic state. 96 In contrast to
classical concepts of physiologic control and homeostasis, the goal of these signals is not to
maintain constancy or equilibrium,97 but rather to successfully adapt to the constant stressors
placed upon it.98 Adaptation to these stressors is characterized by changes in signaling between
regulatory components of the body, spanning from the molecular (cellular) to the systemic level
(organ systems).96 With this, we observe inherent variability in physiological signaling,
representing the natural adaptation to ongoing changes in stimuli and stressors.22,98–101
Variability, from its most basic standpoint, is defined as lack of consistency or fixed pattern. 102
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Therefore, variability observed in physiological signaling suggests responsivity to adaptation to
potential stimuli, rather than lack of physiological control. This concept can be observed in HR
signaling, where increased heart rate variability is suggestive of better autonomic cardiac
regulation.100,101
Physiological variability can be observed across systems and their intrinsic signals,
demonstrated across multiple time scales. This includes variable patterns seen between just
seconds (HR) to months (hormonal cycles). Traditionally, physiological monitoring is
conducted under two assumptions- 1) that these signals are largely stable (not variable) and 2)
that the signal occurs on a singular time scale (linear). Under these assumptions, variability
measurement of these signals is conducted at a singular point in time to provide one “tell-all”
value that is compared to a normative value range for classification. As we have now discussed,
physiological signaling is variable, and therefore single point measurement fails to account for
natural variations in signaling, only giving indication as to what that signal looks like under those
specific internal/external conditions. Furthermore, assumptions of linearity when assessing
physiological signals limit clinicians from observing the depth of physiological signal patterns
across multiple time scales.
Under these assumptions of stability and linearity, traditional metrics of variability such
as mean and SD are often used to assess variable patterns in physiological signals. Mean values
can be quickly compared to a normative value or range established for a given signal. While SD
and other variation metrics do assess variability, these metrics fall under traditional views of
homeostasis, where increased variation is thought to be indicative of poor physiological control
rather than natural adaptation within a signal. While these signals provide very general and
simplified insight into physiological function, these measures fail to recognize the complex and
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fractal dynamics within physiological signals. Complexity is used to assess the interaction
(information signaling) between regulatory components of a system. Changes in complexity
represent an individual’s ability to adapt to the stimuli placed upon it, to maintain or transition to
a given physiological state.98,100 In contrast to variability, complexity assesses the patterns
created during adaptation to stimuli, rather than simply the level of variation from a steady state
(baseline). The concept of variability v. complexity is shown in Figure 3. Variable signals are
not necessarily complex, and complex patterns are not necessarily variable (i.e. reductions in
variability do not automatically reflect reductions in complexity).103 Signals can exhibit
increased variability without complexity, illustrating a non-calculated and potentially
maladaptive response to a stimulus. Furthermore, fractality is an important form of complexity,
used to assess self-similarity of signaling across multiple time scales, such that small scale
patterns represent larger scale patterns. Fractal patterns improve communication efficiency of
information, something observed in the structures of systems (anatomy) and the ability to
translate those signals for a physiological effect. Fractals are widely recognized in anatomical
structures such as the bronchial and arterial trees, where the part (small) looks like the whole
(large).98 When assessing physiological signals, fractal patterns are those that exhibit the same
patterns over small scales (seconds) to long term scales (hours). Examples of fractal patterns in
anatomical structures and physiological signaling is shown in Figure 4. Complexity and
fractality in physiological signaling has been well documented in HR (electrocardiogram)
(ECG), nerve signals (electroencephalogram) (EEG), blood pressure and muscle outputs
(electromyography).98,100,104,105
Both complexity and fractality acts as indicators of the ability of that system/signal to
adapt to the physiological/pathological stimuli placed upon it. That is, loss of complexity and
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fractality are characterized by a reduction of interaction between regulatory components,
resulting in a hindered adaptive capacity of that signal. Individuals with higher baseline (nonstimulated at rest) levels of complexity exhibit a higher readiness and ability to respond to
stressors.100 Similarly, increased power observed in fractal patterns indicates stronger patterns
within the data. With this, reductions in complexity and breakdowns of fractal patterns are
usually observed in cases of aging or disease, often due to isolation or injury to one or more of
the regulatory components of a physiological system.100,106 These complex and fractal signals
exhibit “hidden information” about physiological patterns that cannot be properly be quantified
using conventional linear methods as signaling occurs on both nonlinear and multiple spatiotemporal scales.97,107 Linear methods suggest that the level of variation will be proportional to
the degree of effect (physiological response)106 which is not the case for most physiological
systems. An example of how linear methods can fail to detect the hidden dynamics of
physiological signaling is shown in Figure 5 with HR signals. By conventional standards, these
individuals exhibit the same level of variability, indicated by similar mean and SD values. In
contrast, assessment of complex signaling illustrates the reduction in complexity observed with
aging in the old subject, denoted by a lower entropy value. Therefore, to capture more accurate
and dynamic variability of physiological signals, nonconventional nonlinear methods of analysis
are indicated.104
Complex dynamics of a signal are assessed using a nonlinear analytical approach,
quantified as entropy.18,100,108 Contrary to the entropy definition used in physics, entropy from a
mathematical and analytical standpoint is used to define the dynamic behavior of a variable,
rather than inherent disorder.98 That is, increased levels of entropy actually indicate a higher
degree of physiological control, rather than disorder in signaling. Entropy analysis of
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physiological variables began in the early 1990’s,108 but has yet to be defined in many
physiological signals. To date, entropy analysis has primarily been used to define nonlinear
variability patterns in HR, EEG (brain waves) and electromyography.19,20,105,109 Analysis of
these variables suggests that reductions in entropy are observed with aging and disease,
representing the decrease in complexity (regulatory signaling) and compromised ability to adapt
to stimuli of these signals/systems. With this, reduced entropy levels have been observed in
older populations, individuals with coronary artery disease, Alzheimer’s and
epilepsy.18,100,105,110,111 Similar to these pathological conditions, injury to gas exchange during
COVID-19 infection may result in reduced entropy levels of SpO2 signaling. This would suggest
a decreased ability to maintain normoxic conditions with the increased stress of injury placed on
the cardiorespiratory system, observed as exacerbations or hypoxemic episodes. Entropy
analysis can be utilized to assess multiple types of nonlinear dynamics within SpO 2 signals,
including patterns of regularity, complexity and fractality. Each of these nonlinear analytical
approaches and how they will be used to assess these patterns in SpO 2 signaling will be
discussed here.
The most basic form of nonlinear variability analysis, sample entropy is used to quantify
the regularity of a variable in a time series, a method that is recognized amongst cardiovascular
dynamic variable measurement.18 The concept of sample entropy is displayed in Figure 6. More
irregular signal patterns exhibit higher amounts of information, and therefore increased sample
entropy. In contrast, more regular and predictable patterns exhibit less information, and
therefore lower sample entropy. More regularity in signaling may be indicative of decreased
sensitivity of the signal’s regulatory components to stressors, and demonstrated by less
informational regulatory inputs/outputs to physiological (SpO2) signaling.108 Several studies
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have shown that differences in sample entropy can distinguish between normal and diseased
participants with reductions in entropy occurring with pathology.19,112,113 For example, increased
regularity has been observed in EEG signals during an epileptic seizure, as well as decreased
entropy in ECG signals during heart failure.98,114 Reductions in entropy may also be predictive
of future mortality from pathology.95,98 Injury to the gas exchange process and therefore SpO2
signaling observed during/after COVID-19 infection may contribute to increased regularity in
signaling, denoted by decreased sample entropy levels in these individuals, but this has not yet
been studied.
MSE quantifies the complexity of a variable in a time series and employs cross-scale
correlations by calculating the sample entropy of a time series and its multiple derived sub-time
series.18 Multiple time series are created by repeated downsampling of the data by averaging
adjacent data points together. That is, variability is quantified as sample entropy levels for “beat
to beat” measurement of SpO2, including analysis of every consecutive SpO2 value (scale 1) up
to analysis of the average of every 10 consecutive SpO 2 values (scale 10). Visualization of the
downsampling process is depicted in Figure 7. Interpretation of these sample entropy levels
across scale gives indication of complexity v. randomness in a signal. If the downsampling
process cancels out sample entropy, a signal exhibits randomness rather than complexity. This
suggests that non-physiological “noise” created the variations in the signal, rather than calculated
engagement of a system in an effort to adapt to a stressor, creating a false front of complexity
that is not consistently observed over different time series. Continuous increases in sample
entropy levels across scale despite the downsampling process, however, suggests true complexity
within a signal.110 Complexity observed in SpO2 signaling indicates that there are patterns to be
recognized within the signal, rather than random fluctuations that cannot be quantified. As
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previously discussed, complexity has further been defined as dynamic interaction of regulatory
components that work together to allow for adaptation to stressors.18,100 Therefore, this analysis
indicates the ability of SpO2 to properly regulate itself, despite the potential stressors placed
upon it (COVID-19 related injury). Previously used to analyze other physiological variables,
reduced MSE has been indicated as weakened engagement of the control system (reduced
adaptive signaling amongst its regulatory components)18,95 and has been shown to be predictive
of future decline and poor health outcomes.20 Similarly, as previously mentioned, aging and
disease has been shown to result in decreased complexity signaling.18 Therefore, persisting
injuries sustained during COVID-19 infection could emulate that of early aging to the system
and its structural units, seen as decreased complexity.
The final nonlinear method, DFA, is used to identify fractal-like (self-similarity) patterns
in a fluctuating time-series,18 where small scale patterns are representative of the larger scale
pattern.100 DFA assesses self-similarity patterns of a variable across multiple time scales using
correlations.18,100 This method further allows researchers to distinguish meaningful fractal
properties from potentially random and nonphysiologically influenced patterns,100,104 adding to
the specificity of this analysis. As previously mentioned, fractality in signaling suggests that
variations over a small amount of time are representative of longer time series. While smaller
scales may be representative of larger scales, this method also allows comparison of complexity
levels between scales,18 which may be a helpful indicator for researchers of future investigations
as to what is the most informational and efficient length of signal monitoring is to properly
capture and assess these patterns. By confirming that SpO2 signaling is in fact fractal, it allows
researchers to now classify significant patterns in signaling, similar to that of ECG patterns. 106
Similar to other nonlinear metrics, decreased fractality of physiological signals occurs with aging
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and disease.100,106,111 This breakdown of fractal patterns may be associated with excessive
regularity (similar to that of decreased entropy), classified by repetitive, periodic (and most
likely pathological) signaling.100,104,115 COVID-19 infection could potentially reduce the power
observed in fractal patterns of SpO2, serving as a predictor of adverse outcomes such as future
respiratory decline. Collectively, the utilization of nonlinear analysis of oxygen saturation
variability to supplement traditional linear methods will provide a novel perspective of complex
control of gas exchange and oxygenation homeostasis as it relates to potential persisting injury
from COVID-19 infection.
Bhogal et al. was the first to attempt to quantify “normal” oxygen saturation variability
using continuous SpO2 monitoring in adults, as it has only been previously established in infants.
This study functioned to provide an important baseline for understanding the intrinsic patterns
within oxygen saturation variability, as much of its theory was based upon variability measures
of other physiological signals (i.e. heart rate variability). These novel findings showed that
oxygen saturation variability exhibits a fractal-like pattern, and that variability is better indicated
by long-term measure as denoted by increased complexity in long-term scales. Bhogal also
identified an inverse relationship between SpO2 and sample entropy, where there was higher
entropy seen at lower SpO2 values. Findings suggest that there is tighter control system coupling
at lower saturations, further suggesting that system uncoupling seen in aging and disease could
be indicated by lower complexity. Thus, Bhogal and colleagues proposed that nonlinear pattern
analysis could be utilized to study network physiology, examining how organ systems work
together to control a given physiological variable.18 Another study attempted to observe changes
in oxygen saturation variability by introducing healthy individuals to a hypoxic stimulus,
anticipating increased signaling between regulatory components (increased complexity) to be
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activated to maintain SpO2. When exposed to graded normobaric hypoxia, individuals displayed
increased sample entropy and SD fluctuations in SpO2. Nonlinear analysis was also found to be
more sensitive to the stimulus than linear variables, however linear variability measures were
strongly correlated with sample entropy. Furthermore, Costello identified a significant
correlation between entropy and dyspnea during hypoxia, and sample entropy proved to be more
predictive of hypoxemia than other nonlinear analysis variables.95
Although complexity analysis has not been conducted in clinical populations, oxygen
saturation variability has been studied in these individuals. Buekers et al. collected seven-day
continuous pulse oximetry measurement in 20 individuals with COPD. Results revealed an
average daily fluctuation of 10.8% for these subjects, with 3.2% fluctuations during 5% of
daytime resting values.94 These findings reiterate previous concerns of false identification of
acute exacerbations when discounting natural fluctuations 18,94 and represent the applicability of
extended continuous SpO2 measurement in individuals with respiratory conditions.94 Therefore,
nonlinear variability analysis can be used to observe the natural variability of SpO2 signaling
over an extended period of time, and therefore define true bouts of potential hypoxemia in these
populations.
Figure 3. Variability v. Complexity99

Concepts of variability compared to complexity. Variability in a signal, demonstrated as large deviations from
the mean of a sine wave dones not equate to complexity. This concept can be observed in a signal that is
variable but not complex (left), complex but not variable (middle), or both variable and complex (right).
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Figure 4. Fractals in Anatomical Structures and Physiological Signaling100

Examples of fractal patterns observed in anatomical structures and physiological signaling. Spatial patterns are
observed in anatomical structures such as arterial tree. HR signaling fluctuation patterns appear similar for
smaller time scales of three minutes (bottom) as they look at larger scales of 30 minutes (middle) and 300
minutes (top).
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Figure 5. Linear and Nonlinear Measurement of Heart Rate Variability100

Variability analysis of a heart rate tracing of a young (top) and old (bottom) subject. Linear methods of
variability mean and SD suggest nearly identical levels of cardiovascular control between subjects. Nonlinear
analysis of variability using entropy, however, suggests that the complex cardiovascular dynamics are much
lower in the old subject than the young.

Figure 6. Examples of Sample Entropy116

Examples of signals with varying levels of sample entropy. More irregular signals exhibit higher levels of
sample entropy (orange) while more predictable signals exhibit lower sample entropy (red).
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Figure 7. Downsampling Process Used for MSE Analysis110

Examples of the downsampling process for MSE anaylsis for scale 2 (A) and scale 3 (B). Each scale is created
by averaging adjacent data points together. For scale 2, every two consecutive data points are averaged
together to create a singular value (y1). For scale 3, every three consecutive data points are averaged together
to create a singular value. This process is repeated for a given number of scales throughout the time series or
data collection period.

Cardiorespiratory Network Physiology Analysis
Just as singular signals have regulatory components that exchange information, organ systems
have similar structures of regulatory components that interact for proper function as well. These
regulatory components create a physiological network that is in constant communication. An
example of a network components and how they interconnect are displayed in Figure 8. The
nodes of a network represent each regulatory component while the edges demonstrate the
information signaling that connects them. This can be seen as system coupling, and is observed
throughout physiological processes as control systems work together to maintain their
perspective functions.23,107 Examples of coupled physiological systems include
cardiorespiratory, cardiovascular, neuromuscular, neuroendocrine systems, etc. These integrated
systems are again composed of several regulatory components that interact in a network,
constantly exchanging information between them to elicit physiological responses. Using
exercise as an example, network interactions are stimulated amongst several components of the
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cardiorespiratory system, including HR, breathing rate, blood pressure and skin temperature.
These components all communicate bidirectionally between each other to maintain adequate
blood flow to working muscles, avoid hypoxemia, regulate body temperature, adjust blood
pressure to accommodate increases in HR in a simultaneous manner. Injury to one or more of
these components therefore can consequently cause an entire physiological network to
breakdown. These types of breakdowns are observed during aging and disease and can be
classified as system uncoupling. In the example above, this means the cardiovascular and
respiratory systems are no longer communicating to allow for adequate adaptation to the stimuli
placed upon it, resulting in poor physiological or pathological control of its signals (i.e.
tachycardia for HR, hypoxemia for SpO2, heat stroke for skin temperature).
These network interactions amongst physiological systems can be quantified and compared
using network analysis. Similar to sample entropy levels assessed within singular physiological
signals, these interactions of information exchange between multiple physiological signals are
measured as transfer entropy.93 Reductions or interruptions in network signaling are
demonstrated with disease and aging, and are indicated by reduced transfer entropy levels. In a
healthy working network, exposure to physiological or pathological stimuli should evoke an
increase in network information signaling amongst regulatory components, denoted by an
increase in transfer entropy levels. In cases of aging and disease, degradation of network
signaling is observed (reduced transfer entropy), compromising the ability of that
system/network to adapt to the given stimulus. While not extensively studied in the
cardiorespiratory system, network analysis has been conducted on other physiological systems
such as the brain. The brain as a network has been assessed not only at rest, but under several
pathological stimuli including network responses to insomnia, depression, mental disorders and
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post-traumatic stress disorder.21,23,109,117,118 These investigations successfully captured
significant information processing between components of neurological signaling and indicate
that pathological stimuli may result in negative alterations to the system such as reductions in
transfer entropy levels within the network. Negative alterations to these networks may be
suggestive of systemic risk, observed as vulnerability, symptomology and adaptability.21–23,98
The results of these studies also suggest that there may be a hierarchy amongst the regulatory
components of a system, suggesting that certain parts of a network may be more influential to
desired system outputs than others. In the cardiorespiratory system, for example, physiological
signals may differentially contribute to the maintenance and regulation of SpO 2, and vice versa.
Reductions in network signaling due to aging or disease therefore also may result in modification
of this structural hierarchy,98 where some signals may have to overcompensate for the injury to
others, or there is failure to compensate altogether. By identifying points of potential injury and
determining the magnitude to which they contribute to other signals, clinicians and researchers
may be more equipped to understand and treat signals of interest with therapeutic intervention.
In summary, network analysis is used to assess the degree of integration amongst the regulatory
components of a system/network, assess the ability of these components to adapt to potential
stressors, and to identify a hierarchy of physiological structure and control amongst these
components (i.e. the magnitude to which each component contributes to proper function).
As previously discussed, the cardiorespiratory system is made up of several regulatory
components that continuously interact to maintain proper physiological function. These include
SpO2, HR, breathing rate and skin temperature. In cases of cardiorespiratory injury, often
observed during and following COVID-19 infection, these regulatory components may not
properly compensate for the stressors placed up on them, resulting in dysfunction of the overall
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system seen as cardiorespiratory uncoupling. Representation of the signals used for the proposed
cardiorespiratory network analysis are displayed in Figure 9. These signals were explored due to
their established physiological interdependence as well as due to the potential effect COVID-19
infection may have on each component. Post-COVID effects on HR have been reported due to
inflammatory damage to heart tissue at ACE2 receptors and to the endothelial tissue of the
heart’s microcirculation.119 These persisting injuries may cause heart palpitations,
breathlessness, and autonomic dysfunction of HR regulation.120,121 Other COVID-related
respiratory symptomology include exacerbations of hypoxemia and dyspnea followed by
increases in respiratory effort to compensate for low SpO2 and decreased air flow. These
symptomologies simultaneously effect SpO2, respiratory rate and subsequent HR regulation due
to respiratory control. Similar to the heart and lungs, endothelial tissue throughout the body is
damaged, leaving the body’s microcirculation in a damaged and procoagulant state. 9,10,119,121
These injuries may cause disruptions to thermoregulation in the body, effecting skin temperature
as a result. Thermoregulatory signaling may result in changes to respiratory rate and HR,
subsequently affecting SpO2. Furthermore, neurological manifestations of COVID-19 indicate
injury to the hypothalamus, a portion of the brain that is responsible for several physiological
processes including thermoregulation, respiratory control and cardiovascular regulation- directly
impacting each of the proposed signals.122,123 As the effects of COVID infection extend further
than just the lungs, it is important to explore the cardiorespiratory system as a whole when
discussing these highly interdependent signals.
Network physiology analysis assessing cardiorespiratory signaling regarding SpO2 control
has only been conducted once prior to the current work. Costello et al. employed a network
physiology approach to understanding cardiorespiratory control of oxygen saturation variability,
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assessing transfer entropy between simultaneous respiratory rate, tidal volume, minute
ventilation, HR, SpO2, and both end-tidal O2 and CO2 signals during exposure to graded
normobaric hypoxia.93 This novel analysis revealed a significant exchange of information
between these cardiorespiratory signals, giving insight into the integrity of the overall
physiological system. The current work will set out to understand the flow of information
between similar cardiorespiratory variables (SpO2, HR, respiratory rate and skin temperature)
when challenged with a pathological (previous COVID-19 infection) rather than environmental
(graded hypoxia) stimulus.

Figure 8. Example of General Interconnect Network124

Example of an interconnected network. Nodes represent the components of a network and edges represent the
relationships that connect them. In physiological analysis, nodes represent physiological signals, and edges
represent the exchanges of information that are communicated between them.
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Figure 9. Proposed Cardiorespiratory Signals for Network Physiology Analysis

Representation of proposed dynamic interaction of transfer entropy (T E) between cardiorespiratory signals
including: SpO2 (A), ECG (B), respiratory rate (C) and skin temperature (D).

Summary
The acute lung injury, chronic inflammation and subsequent respiratory complications observed
in COVID-19 patients have important implications for potential sequelae on the respiratory
system and methodology that should be used to assess recovery status in these individuals.
Existing follow-up studies evaluating respiratory function in COVID-19 survivors suggest that
abnormalities seen during the infection phase may persist months into the recovery period,
similar to that seen in survivors of SARS-CoV, MERS-CoV, ARDS and COPD.6,8,56,57,59,60,76–
78,125,9,11–13,41,43,53,55

With this, chronic inflammation poses its own enduring challenges for

COVID-19 survivors including a suppressed immune system and increased susceptibility for the
development of future infections and general respiratory decline.3,6,9,40,42,62,63 These attributes of
COVID-19 infection and recovery can be assessed both in a clinical and home setting, allowing
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for increased accessibility to this population. Standard pulmonary function values identify
restrictive lung patterns and elaborate on the source of diminished lung capacity observed in
these individuals.17,55,68,69,71,75,76 Additionally, both systemic inflammation and inflammation
specific to the airway can be assessed using salivary biomarker samples 3,5,7,12,40,62,63 and exhaled
nitric oxide measurement,80–82,87,126 respectively. Furthermore, quantifying oxygen saturation
variability and transfer entropy in COVID-19 patients will offer mechanistic insight into the
persistent hypoxemia that is hallmark to this population and the degree of control exhibited by
the cardiorespiratory system as it functions holistically,5,18,89–91,93–95,100 in contrast to standard
spot-check measurement. These methodologies will collectively allow for evaluation of
respiratory function in COVID-19 survivors and supplement the forthcoming literature of
recovery assessment and prolonged respiratory health in this population.
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Chapter 3: Methods
Participants
57 adults (both men and women) ages 18 to 65 were recruited to participate in this study. The
participants were allocated to two groups- one case group of participants who have previously
been diagnosed with COVID-19 infection (n=24) and a control group with no history of COVID19 (n=33). The diagnosis of the participants in the case group was confirmed via documentation
of a clinical diagnosis including either a positive viral test or positive antibody test. Participants
in the control group were required to provide documentation of both a negative viral test to
indicate no active infection and a negative antibody test to rule out previous infection.
Documentation of one of these negative tests was required in the two weeks prior to the
participant enrolling in the study. All participants were required to provide documentation of a
negative viral test within two weeks prior to contacting researchers to prevent possible
transmission. Sex, age, and race-/ethnicity were similar between recovering COVID-19
individuals and healthy controls. Prior to participation, subjects completed a screening
questionnaire for COVID-19 exposure/infection to confirm their eligibility. The screening
questionnaire provided a list of common COVID-19 symptoms and asked about their recent
travels and contact with persons who had COVID-19 in the last two weeks as well as any
symptomology they may have experienced within the last two weeks. All participants provided
oral informed consent prior to study involvement in accordance with university institutional
review board guidelines.
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Exclusion Criteria
Participants were excluded from the study if they were under the age of 18 and/or if they had a
pacemaker. Additionally, participants who experienced symptoms, had contact with someone
who has COVID-19, or have traveled out of state in the two weeks prior were not allowed to
participate in this study. Participants who were unwilling or unable to engage in Zoom calls with
the researcher were also excluded from the study. Finally, participants who did not complete
both respiratory measures (pulmonary function and exhaled nitric oxide) were excluded from
analysis.

Study Design
This study used a case-control design, with the case group consisting of participants with a
history of COVID-19 infection and a control group of participants with no history of COVID-19.
The study was conducted remotely with limited to no face-to-face interaction to prevent potential
exposure of both participants and researchers to COVID-19. All physiology measurements were
completed by the participant with assistance from research personnel via Zoom. Due to the
remote functionality of this study, the consent process included an oral informed consent
conducted via Zoom. During this Zoom meeting a member of the research team explained the
study purpose and methods to the potential participant. Oral consent was then provided by the
participant if they met all inclusion criteria and agreed to participate in the study. All study
procedures were approved by the Syracuse University Institutional Review Board.
Upon completing the oral consent process, researchers coordinated a date and time to
delivery study equipment to the participant’s home. The equipment was delivered in two boxes,
one (box 1) with cardiovascular equipment and the other (box 2) with respiratory equipment.
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These two boxes corresponded to two additional Zoom meetings. When university research
restrictions lifted, two brief, socially distanced 15-minute in-person meetings were held at the
Syracuse University Human Performance Laboratory for data collection in place of these two
Zoom meetings. Two separate meetings were decided upon to minimize participants burden and
to maximize the efficiency of testing. Box 1 containing cardiovascular equipment included a 24hour ambulatory blood pressure monitor, an activity monitor, a fingertip pulse oximeter, a digital
scale, a HR monitor, a saliva collection kit (containing a collection tube and funnel for saliva
collection aid) and an instruction sheet for all measures. Box 2 containing respiratory equipment
included a handheld spirometer to assess lung function, a handheld NiOX machine to measure
airway inflammation, an Equivital EQ02 LifeMonitor (chest bioharness) to assess continuous
blood SpO2 and cardiorespiratory measures and a new instruction sheet.
Prior to both meetings participants were asked to undergo a three-hour fast (no food or
sugary drinks for at least three hours) as food or drink containing nitrates may affect FeNO
measurement.127,128 Participants were also asked to refrain from exercise, alcohol, smoking and
caffeinated beverages for at least 12 hours. Equipment from each Zoom meeting besides the
activity monitor was picked up the day following the meeting. The activity monitor was picked
up nine days after the first meeting at the participant’s home after completing data collection. At
this time, researchers dropped off a standard blood pressure cuff as compensation for
participation in the study. Full study design is displayed in Figure 10.
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Figure 10. Study Design

Study design from initial participant recruitment through completion of all study measures.

Anthropometrics
Height, weight and body composition were collected for anthropometric data. Height was selfreported by the participant to researchers during remote collection. This measure has been found
valid for assessing height in adults under the age of 60.129 For those who completed in-person
data collection, height was also assessed using an automated stadiometer in addition to selfreported measurement. A digital scale equipped with bioelectrical impedance analysis was used
to obtain both weight and body fat percentage. Body mass index was calculated from height and
weight as kg/m2.

Pulmonary Function Testing
Lung function was assessed via pulmonary function testing using a handheld CareFusion
MicroGP Spirometer (Becton, Dickinson and Company, Franklin Lakes, NJ). This device was
successfully applied in home spirometry monitoring in diseased populations where it
demonstrated sufficient validity and reliability, as well as highly predictable in early
identification of disease progression and FVC decline in this cohort.130 Additionally, this
spirometer has been standardized against both American Thoracic Society and European
Respiratory Society guidelines.131 A Viromax™ bacterial-viral filter (A-M Systems, Sequim,
WA) was attached to the spirometer (>99.99% viral filtration efficiency) to prevent the spread of
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COVID-19 through airborne aerosol particles.132 Participants were asked to wear the provided
nose clip during the test to ensure all exhaled air is directed through the mouth. They were then
asked to assume a seated, upright position with feet uncrossed and flat on the floor. After
inserting the viral filter mouthpiece, participants input their subject information (sex, age, height)
as well as an ethnic correction factor as directed by the CareFusion MicroGP company. Three
trials were completed consisting of one deep breath that provided both absolute and percentile
(of expected value for inputted subject information) of four measures of pulmonary function:
FVC, FEV1, FEV1/FVC and PEF. FVC is the amount of air exhaled forcefully and quickly out
of the lungs after maximal inflation and emptying the lungs completely. FEV1 is a measurement
of the amount of air that is expired in the first second (1 second) of the test. FEV1/FVC is the
proportion of the total forced vital capacity that is exhaled in 1 second. PEF is a measurement of
air flow out of the lungs and the maximal flow of air achieved during the sharp expiration of the
test. These four lung function measurements were collected simultaneously during the same
spirometry maneuver and give insight into lung function, strength of expiratory muscles and the
general condition of the airway. They were then asked to place the nose clip on their nose and
take a deep breath, maximally inflating their lungs. Participants then placed the mouthpiece in
their mouth and close their lips tightly. Research personnel instructed the participant to exhale as
quickly and forcefully as they could into the mouthpiece. To ensure the participant fully emptied
their lungs, the researcher encouraged them to exhale for three seconds even after the lungs felt
empty to void of any excess air. Participants completed this maneuver for a total of three times,
and the highest score of the three trials was taken as their final score for each measure.
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Airway Inflammation
Airway inflammation was measured by quantifying exhaled nitric oxide levels using the NiOx
VERO™ FeNO device (Circassia, Morrisville, NC). Elevated nitric oxide levels in expired
breath are indicative of airway inflammation caused by respiratory distress. This device has
shown sufficient validity and reliability in monitoring of patients with asthma.133 The NiOx
VERO™ FeNO device uses a disposable mouthpiece to minimize transmission potential.
Although this type of testing is not an aerosol generating procedure, the disposable mouthpiece
included a bacterial-viral filter with over 99.97% viral filtration efficiency and has been tested
with microbes up to four times smaller than SARS-CoV-2, indicating its efficiency in
filtration.134 Prior to beginning the testing procedure, participants were instructed to assume a
seated, upright position with feet uncrossed and flat on the floor. This test was completed by
first inhaling through the mouthpiece as directed by the prompt on the display screen followed
by exhaling into the mouthpiece at a steady flow rate of 50 mL/s for approximately 10 seconds.
The NiOX VERO utilizes an electrochemical sensor, reporting the fractional concentration of
exhaled nitric oxide in approximately 60 seconds on the display screen.

Arterial Blood Oxygen Saturation
Noninvasive spot check pulse oximetry at rest was conducted to measure arterial blood oxygen
saturation (SaO2) using a fingertip pulse oximeter on the index finger. The pulse oximeter
measures infrared and red-light wavelength absorption v. reflection to determine the ratio of
oxygenated hemoglobin to total hemoglobin, reported at as a percentage.
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Continuous Cardiorespiratory Monitoring
Continuous SpO2 monitoring and other continuous cardiorespiratory measures were collected
using the Equivital EQ02 LifeMonitor (Equivital Hidalgo, Cambridge, UK). This system is a
three-piece ambulatory multi-parameter telemetry device consisting of a bioharness with three
textile sensors that was worn around the lower chest attached to a Sensor Electronics Module
(SEM) and wired fingertip pulse oximeter. The Equivital EQ02 LifeMonitor has previously
demonstrated high validity and reliability for ECG and skin temperature signaling and the
feasibility of wear for collecting multiple signals simultaneously makes it desirable for
continuous physiological data collection.135,136 Although the device has not been implemented
with diseased populations, it has been used in several cohorts including healthy individuals,
military personnel, athletes and occupational measurement.135–137 Its primary use was for
continuous pulse oximetry measurement but was also used to simultaneously collect important
variables of cardiorespiratory function including HR derived from ECG, respiratory rate, skin
temperature. SpO2 was collected using the Nonin wired pulse oximeter ancillary sensor,
connected directly to the sensor belt, relaying SpO2 values 1/15 s (2 Hz) directly to the SEM to
create one continuous signal. Two chest leads built into the textile sensors of the sensor belt
captured ECG at a sampling rate of 256 Hz. HR was then calculated directly from the ECG
channel using the cyclic measurement function in LabChart. Respiratory rate was derived using
the cyclic measurement function directly from an intrinsic chest expansion signal, captured using
the textile sensors located on the chest at sampling rate of 25.6 Hz. Skin temperature was
collected every 15 seconds via medical grade infra-red thermometer located on the sensor belt
under the left arm.
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Prior to device setup participants were asked to remove any nail polish from their index
finger, any lotions or oils from their chest region and to wash their hands thoroughly. The
researcher instructed the participant in how to set up and wear the device on the Zoom meeting.
The participant was instructed to moisten the textile sensors using clean water to help keep close
contact with the skin and strengthen all signals. The bioharness was worn with direct contact
with the skin under any sort of clothing or undergarment. The pulse oximeter was worn on tip of
the index finger of the participant’s choice, usually their nondominant hand. Once the device
setup was complete the participant was asked to wear the Equivital EQ02 LifeMonitor for four
daytime hours during which they completed their normal daily activity. Data collection was
standardized to begin between 8:00-10:00 am to account for the circadian rhythm of this signal
and was carried out for four continuous hours. Four-hour data collection was chosen as the
device previously displayed superior reliability during shorter time periods (four hours v. eight
hours) however was still long enough to capture the natural fluctuation of SpO2 signals. A
previous study showed that a minimum of one hour was necessary to observe SpO 2 variability,
however this same study also observed that oxygen saturation variability was predominantly
made up of long-term variations.18 Therefore, to see this higher degree of variability, a longer
collection window was chosen. Participants were asked to refrain from consumption of caffeine
and alcohol, exercise, smoking, prolonged exposure of equipment to direct sunlight, and
immersion of any equipment in water as these can affect one or more of the cardiorespiratory
signals.
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Oxygen Saturation Variability
Oxygen saturation variability was calculated using both linear and nonlinear analysis
methodology using the continuous SpO2 signal captured over four hours. Linear analysis is a
more elementary method of looking at variability, including variables such as mean, SD, RMS,
and average hourly change. However, to get the true essence of SpO2 fluctuations, nonlinear
analysis looking at entropy patterns on several scales is more representative of true variations in
SpO2. Nonlinear analysis methods include sample entropy assessing the regularity and
predictability of the variable, MSE assessing the complexity of the variable, and DFA to identify
fractal-like behavior of the variable. Low entropy values of SpO2 have previously indicated
cardiorespiratory uncoupling and lack of physiological control. Finally, network physiology
analysis was used to quantify the interaction between four of these cardiorespiratory signals
(continuous SpO2, HR derived from ECG, respiratory rate, and skin temperature) measured as
transfer entropy.

SpO2 Signal Processing
SpO2 was collected every 15 seconds continuously for four hours at a sampling rate of 2 Hz. All
files were downloaded from the device to the Equivital Manager software and subsequently
converted to a LabChart files consisting of eight channels.138 Data files were considered
complete if the subject completed at least 3.5 hours of data collection, and the raw signal was not
lost for greater than 15 minutes during collection due to device removal or excessive artifact.
Complete files were then “cleaned” using a combination of internal arithmetic functions within
LabChart. The algorithm included Threshold, Smoothsec, Window and NanRemover
functions.139 A summary of each function and its use for the data can be found in Table 2. A
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minimum threshold of 90% was chosen for the data file, such that if the raw signal read values of
below 90%, the algorithm interpolated the mean value for the overall signal in its place. This
threshold was chosen to eliminate artifact and preserve the natural variability of the signal as it
can be assumed that none of our participants were experiencing severe hypoxemia such that they
would require a supplemental oxygen requirement. Examples of a raw and clean data file can be
seen in Figure 11.
Table 2. LabChart Arithmetic Cleaning Functions
Threshold (90)

Detects data points that fall below 90%

Smoothsec (1)

Calculates a moving average in a specified
sliding window of one second
Detects SpO2 data within the range of 90100%, any data points outside this range
assigned a zero
Removes Not a Number (Nan) and out of
range data from data file to create one
continuous signal

Window (90,100)

NanRemover

Figure 11. Example Raw and Clean SpO2 File
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Examples of raw (top) and cleaned (bottom) extended SpO2 files for four continuous hours. Cleaned files
include data file treated with combination cleaning functions from Table 2.

Linear Analyses
Linear analysis of clean files was conducted directly in LabChart using the DataPad function.
SpO2 mean, SD, and RMS were calculated for the entire four-hour collection period. The range
for each of the four hours was calculated individually and these four values were then averaged
to derive the average hourly change in SpO2 for the overall file. An example data output for
linear analysis from DataPad can be found in Figure 12.
Figure 12. Example Linear Oxygen Saturation Variability DataPad Output

Example of four-hour output of linear oxygen saturation variability measures using DataPad function in
LabChart.
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Nonlinear Analyses
1.

Sample Entropy. Sample entropy was calculated to assess the degree of regularity of the

continuous SpO2 signal in our time series (four hours). This value calculates the probability that
an event (SpO2 fluctuation) during a set window length described as “m”, with tolerance “r”, will
be repeated later in a time series.18,140 For the current analysis, sample entropy was calculated
where “m” was set at 2 and “r” at 0.2 as described in previous studies.18,140,141 Low sample
entropy indicates regularity in a signal and decreased complexity, and potential isolation of
regulatory components of cardiorespiratory control.140 In contrast, high sample entropy suggests
higher irregularity in a time series, and increased engagement of cardiorespiratory control.18
Sample entropy was calculated using MATLAB codes shared at PhysioNet by Goldberger et al. 97
2.

Multiscale Entropy. MSE was assessed by calculating sample entropy across 10 different

time series and plotting each value against one another to determine if these scaled sample
entropy values are correlated.18 Each scale functions to evaluate the time series at a
progressively lower resolution (termed “coarse graining”), achieved by averaging consecutive
SpO2 values of increasing length. For example, at scale 1, sample entropy is calculated for the
original time series. At scale 2, sample entropy is calculated by averaging every two consecutive
SpO2 values, functioning to down sample the signal x2. This process is repeated up to scale 10,
where sample entropy is calculated for every 10 consecutive SpO 2 values, and the original time
series has been coarse grained x10.110 The resulting plot displays sample entropy across multiple
time series, indicating the change in complexity based on the direction of the change in values.
This process also functions to expose randomness (decreased complexity) of a signal through
coarse graining, reflected by a decrease in sample entropy as scale increases. 18 In contrast, if
sample entropy values remain the same or increase concurrently with scale, this indicates
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increased complexity within the signal. MSE analysis was conducted using MATLAB coding
shared at PhysioNet.97,141
3.

Detrended Fluctuation Analysis. DFA was conducted to identify fractality (self-

similarity) within SpO2 signals by calculating the RMS of fluctuation across different time series
(scales) plotted against one another on a log-log scale.18 The signal is fractal if this plot exhibits
linearity. The slope of this line was then determined as the scaling exponent, denoted as alpha
(α), for both short- (α1) and long-term (α2) time series. α values of 0.5 indicate uncorrelated
random data.18 α values of greater than 0.5 to 1.0 indicate complexity of a signal,140 with a slight
decrease in complexity at α >1.0. DFA was conducted using software at PhysioNet developed
by Goldberger et al.97
4.

Network Physiology Analysis. Network analysis of the cardiorespiratory control system

was conducted by calculating bidirectional transfer entropy between continuous physiological
signals of SpO2, HR, respiratory rate and skin temperature for one hour of the data collection
period. Transfer entropy reflects both the direction and magnitude of information processing
between these regulatory components of the physiological system, defining the interaction of
complexity between each signal over the same time series. Network analysis was conducted
using an open source function in MATLAB shared at PhysioNet.97

Biobehavioral Correlates of Cardiorespiratory Function
Potential biobehavioral correlates of cardiorespiratory function were explored in order to gain
insight into potential modifiable factors that could impact cardiorespiratory recovery in a
COVID-19 setting. Chronic elevations in inflammation post-infection may contribute to ongoing
injury, resulting in reduced respiratory function in recovering individuals. Increased physical
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activity levels may be protective to cardiorespiratory function while low physical activity levels
and increased sedentary time amongst recovering patients due to persisting symptomology (or
non-infection related reasons) may result in worsened inflammatory profiles as the antiinflammatory effects of activity are not seen. Disease severity may give an indication of whether
persisting impairments are related directly to the acute injury caused by infection.

Salivary Biomarkers
Systemic inflammation was assessed using salivary C-reactive protein (CRP) and cytokine (IL1β, IL-6, IL-8 & TNF-α) levels via a passive drool. These cytokines have been deemed major
components of the “cytokine storm” seen in COVID-19 patients and are significantly elevated
due to infection. Participants were asked to refrain from eating a major meal for one hour prior
to measurement and to rinse their mouth with water 10 minutes before collection. The
measurement was conducted using passive drool through the Saliva Collection Aid (Salimetrics,
Carlsbad, CA) and into a SalivaBio’s 2 mL cryovial. Participants were asked to fill the vial to
the line provided, collecting two separate 1.8 mL of samples. Samples were stored at -80
degrees Celsius until they were shipped to Salimetrics, Carlsbad, CA for analysis. Using the
Salimetrics ELISA “sandwich” immunoassay kits, saliva samples were analyzed in duplicate and
assayed for CRP, IL-1β, IL-6, IL-8, and TNF-α concentrations in pg/mL.

Physical Activity and Sedentary Time
Physical activity levels in all participants were assessed using tri-axial accelerometry.
Participants continuously wore an ActiGraph wGT3x-BT accelerometer (ActiGraph LLC,
Pensacola, FL) around the waist and above the right hip 24 hours a day (except when
participating in water-based activities) for nine consecutive days. Accelerometry data was
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downloaded to the ActiLife Software (version 6.13, ActiGraph LLC) to be analyzed. Data was
collected at 80 Hz and processed in 60-second epochs. Sleep wear and awake wear time were
distinguished using a previously validated algorithm (SAS syntax available at http://
www.pbrc.edu/pdf/PBRCSleepEpisodeTimeMacroCode.pdf) developed by Barriera et al. (2018)
using SAS version 9.4.142 Activity was measured as moderate-to-vigorous (MVPA) based on
activity counts per minute. MVPA was defined as greater than 2020 activity counts per
minute.143 Sedentary time was defined as any movement ≤25 counts per 15 seconds.144,145 Nonwear time was determined as 60 or more consecutive minutes of zero activity counts, with the
exception of 1-2 minutes of activity counts between 0 and 100.143 A complete day of
accelerometer data collection was determined as at least 10 hours of awake wear time. A
minimum of 4 days of complete wear data was considered valid and included in the final
analysis.143

Infection History and Experience
After the completion of all Zoom meetings, participants were sent an email containing a secure
link via Research Electronic Data Capture (REDCap) to an online health survey consisting of a
compilation of questionnaires assessing infection experience in participants with a history of
COVID-19 disease as well as a general health history. REDCap is a web-based data collection
system that allows for secure computerized collection and storage of data as well as stratified
randomization algorithms (https://projectredcap.org). COVID-19 infection experience in
recovering individuals was assessed using a survey developed by our researchers that asked
about symptomology and participant experience with COVID-19 infection, including number of
days since positive test, number of symptoms experienced during infection, and disease severity
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rated on a five-point scale based on reported symptomology as per the World Health
Organization’s guidelines.146 Infection experience will be assessed as a potential covariate of
respiratory function, systemic inflammation and physical activity levels within the COVID-19
group. General health history was assessed using a patient health history questionnaire, which
asked participants about chronic cardiovascular, respiratory, liver and kidney diseases.

Statistical Analyses
Descriptive statistics were calculated as mean ± SD. All variables were tested for normality of
distribution and outliers using Shapiro-Wilks test, Q-Q plots, and histograms. Pulmonary
function, exhaled nitric oxide, linear oxygen saturation variability, systemic inflammation and
physical activity measures did not meet assumptions for parametric analysis, therefore we
proceeded with nonparametric analyses. Nonlinear measures of oxygen saturation variability did
meet assumptions for normality, therefore we proceeded with parametric analyses for these
variables only. Group differences in pulmonary function, airway inflammation and linear
oxygen saturation variability between recovering COVID-19 individuals and controls were
assessed using the Mann-Whitney U-Test. Group differences in nonlinear oxygen saturation
variability were assessed using independent samples T-test. Two-way ANOVA was used to
assess group differences in MSE variability to evaluate the effect of both COVID-19 infection
history and scale on MSE only. Categorical group differences were evaluated with Chi-Square.
One-Tail Spearman correlation was used to explore any associations between components of
respiratory function, oxygen saturation variability and measures of systemic inflammation (CRP
and cytokine levels) as well as physical activity (MVPA and sedentary time) in recovering
COVID-19 participants. Partial eta-squared (η2) as a measure of effect size and observed power
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were calculated for all variables to give indication of the strength of potential group differences
observed based on our sample size. Statistical significance will be set a priori at p<0.05. All
analyses were performed using IBM Statistical Package for Social Sciences (SPSS, version 27,
IBM, Chicago IL).
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Chapter 4: Results
Participant Characteristics
Fifty-seven participants consented for this study, completed all respiratory function measures and
were included for analysis of pulmonary function and inflammation levels. Participant
descriptive characteristics are displayed in Table 3. Participants were age, sex, and raceethnicity matched between COVID-19 and Control study groups (p>0.05). Our cohort was
generally normotensive, normoxic and of healthy weight-status and these measures of SaO2,
BMI and body fat percentage were not different between groups (p>0.05).
Table 3. Participant Characteristics

Age (years)
Sex (%)
Male
Female
Race/Ethnicity (%)
White
Hispanic
African American
Asian American
SaO2 (%)
BMI (kg/m2)
Body Fat (%)
Days Since Positive
COVID Disease Severity
COVID Symptoms

COVID+ (n=24)
25.0 ± 9.0

Control (n=33)
24.0 ± 6.0

8 (33.3)
16 (66.7)

12 (36.4)
21 (63.6)

19 (79.2)
0 (0)
3 (12.5)
2 (8.3)
97.92 ± 0.78
24.02 ± 3.45
22.30 ± 4.57
94.0 ± 82.0
2.2 ± 0.83
6.0 ± 5.0

27 (79.4)
0 (0)
4 (11.8)
3 (8.8)
97.75 ± 2.26
25.07 ± 3.52
22.76 ± 4.50
-

p value
.570
.813
1.00
.403
.264
.703
-

*p<0.05
Abbreviations: BMI, body mass index

Respiratory Function
Pulmonary Function and Airway Inflammation
Group differences in respiratory function can be found in Table 4. Both groups exhibited normal
pulmonary function, achieving 80% or above of their predicted values for all pulmonary function
parameters based on participant sex, age, height, and race-ethnicity. Non-parametric
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independent samples analysis revealed that pulmonary function did not differ between our study
groups, such that FVC, FEV1, FEV1/FVC and PEF were not significantly different (p>0.05)
between COVID-19 individuals and controls. Airway inflammation measured as exhaled nitric
oxide levels did not significantly differ between our study groups (p>0.05). Both groups
exhibited slight airway inflammation, but did not reach abnormal levels, minimally surpassing
the cut-off for no inflammation (16 ppb).
Table 4. Full Sample Respiratory Function, Systemic Inflammation and Physical Activity
COVID+ (n=24)

Control (n=33)

p value

Partial η2

Observed
Power

Respiratory Function
FVC, L (%)

4.22 ± 1.01 (102)

.663

.010

.115

FEV1, L (%)

3.45 ± 0.72 (97)

.865

.005

.083

FEV1/FVC (%)

84.88 ± 10.68
(99)
349.63 ± 105.54
(81)
16.61 ± 13.04

4.43 ± 1.06
(102)
3.57 ± 0.92
(95)
81.27 ± 8.93
(94)
372.73 ±
140.61 (80)
20.03 ± 20.11

.293

.034

.275

.370

.008

.101

.285

.009

.108

1206.90 ± 2021.4
302.61 ± 869.4
8.81 ± 16.7
14.86 ± 49.4
1226.72 ± 1642.1

871 ± 944.1
149.05 ± 155.5
5.98 ± 7.9
5.25 ± 5.9
735.16 ±
1112.9

.508
.959
.973
.364
.067

.012
.017
.013
.021
.032

.126
.158
.129
.185
.254

35.37 ± 17.02

35.65 ± 17.49

.925

.000

.050

717.91 ± 166.92

717.82 ±
167.08

.763

.000

.050

PEF, L/min (%)
Nitric Oxide
(ppb)
Systemic
Inflammation
IL-8 (pg/mL)
IL-1ß (pg/mL)
IL-6 (pg/mL)
TNF-α (pg/mL)
CRP (pg/mL)
Physical Activity
MVPA
(min/day)
Sedentary Time
(min/day)

*p<0.05
Abbreviations: η , partial eta-squared; FVC, forced vital capacity; FEV1, forced expiratory volume in 1
second; PEF, peak expiratory flow; IL, interleukin; TNF, tumor necrosis factor; CRP, C-reactive protein;
MVPA, moderate to vigorous physical activity
2
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Oxygen Saturation Variability
Oxygen saturation variability analysis was conducted on a subsample of 40 participants from our
original cohort. Determination of which participants were included in this subsample is depicted
in Figure 13. From the original sample, three participants were lost at follow-up, 10 participants
were lost due to device malfunction, and four participants’ SpO2 data files failed to meet
inclusion criteria, bringing the final sample for SpO2 analysis to n=40. Device malfunction
included participants that wore the Equivital EQ02 LifeMonitor however experienced a failed
SpO2 signal due to connectivity issues between the sensor belt and pulse oximeter (n=10).
Participants who did not complete at least 3.5 hours of data collection or had missing data of ≥15
minutes at a time during the collection period due to excessive artifact from activity and/or
device removal were not included for analysis (n=4).
Participant characteristics for the subsample included for SpO2 analysis are displayed in
Supplementary Table 2. Similar to our overall sample, age, sex and race-ethnicity were similar
between groups (p>0.05). Our subsample was normotensive, normoxic and of normal weightstatus. Additionally, none of these measures of SaO2, BMI or body fat percentage differed
between our study groups (p>0.05). Recovering COVID-19 participants in our subsample were
measured on average 121.0 ± 132.0 days post-infection, experiencing mild-to-moderate COVID19 infection with an average of 5.0 ± 5.0 symptoms). Group differences for all respiratory
function, systemic inflammation and physical activity measures in our subsample can be found in
Supplementary Table 3.
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Figure 13. Inclusion Process for Oxygen Saturation Variability Analysis

Breakdown of inclusion process for participants included in oxygen saturation variability analysis. Of the full
sample of 57 participants, three were lost at follow-up, 10 did not successfully complete data collection due to
device malfunction, and four participants’ data files did not meet inclusion criteria for analysis.

Linear Analyses
Group differences in linear oxygen saturation variability are displayed in Table 5. Participants in
both groups were normoxic and spot check SaO2 values did not differ between groups (p>0.05).
In our subsample, no group differences were observed for any linear oxygen saturation
variability parameters such that mean, SD, RMS and average hourly change were not
significantly different between groups (p>0.05).
Table 5. Linear Oxygen Saturation Linear Variability Group Differences in Subsample
COVID+ (n=16)
Spot SaO2 (%)
Full O2 Mean (%)
Full O2 SD (%)
Full O2 RMS (%)
Avg Hourly O2
Change (%)

98.00 ± 0.63
97.51 ± 0.62
1.12 ± 0.39
97.52 ± 0.62
5.97 ± 1.21

Control
(n=24)
97.71 ± 2.56
97.29 ± 0.68
1.19 ± 0.41
97.15 ± 0.69
6.35 ± 1.35

p value

Partial

Observed Power

η2

.503
.070
.469
.070
.469

.005
.072
.006
.072
.022

.072
.386
.076
.387
.146

Abbreviations: η , partial eta-squared; SaO2, arterial oxygen saturation; O2, oxygen; SD, standard deviation;
RMS, root mean square; avg, average
2
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Nonlinear Analyses
Group differences for all nonlinear analyses of sample entropy, MSE and DFA oxygen saturation
variability can be found in Table 6.
1. Sample Entropy. No group differences in sample entropy over the 4-hour collection
period were observed between individuals with a history of infection and controls
(p>0.05).
2. Multiscale Entropy. Multiscale entropy analysis revealed that oxygen saturation
variability exhibits a complex, but not random, correlated data signal across a 10-scale
time series. This relationship is reflected by an increase in sample entropy concurrent
with the increase in scale (Figure 14). One-way ANOVA reflected no differences in
sample entropy at any time scale (p>0.05) between study groups. According to two-way
ANOVA, while there was a significant factor effect as previously noted (i.e., sample
entropy increases with increasing scale, p<0.05), there was not factor-by-group
interaction (p = 0.068) suggesting that both groups experienced similar increases in
sample entropy with increasing scale.
3. Detrended Fluctuation Analysis. Based on DFA, oxygen saturation variability exhibits
fractality, illustrated by the linear pattern of the scaled signal (Figure 15). DFA was
conducted for both short-term and long-term time scales, where we did not observe a
significant difference between groups for α1 or α2 (p>0.05). This analysis did reveal,
however, that oxygen saturation variability exhibits more powerful complexity during
long-term variation as opposed to short-term, indicated by a mean α2 closer to 1.0 (in
contrast to a mean α1 value closely approaching 1.5).
4. Network Physiology Analysis. Network analysis of SpO2, HR, respiratory rate and skin

62

temperature demonstrated significant bidirectional exchanges of information between
SpO2 and other cardiorespiratory signals over the same time series. These exchanges
information was quantified as transfer entropy levels between signals, displayed by the
graphical representation in Figure 16. The direction and magnitude of transfer entropy
between signals are illustrated by the orientation and thickness of the arrows between
signals, respectively. Transfer entropy between all signals in either direction was similar
between groups (p>0.05).
Table 6. Nonlinear Oxygen Saturation Variability Group Differences in Subsample

Sample Entropy
MSE
Scale 1
Scale 2
Scale 3
Scale 4
Scale 5
Scale 6
Scale 7
Scale 8
Scale 9
Scale 10
DFA
α1
α2

COVID+ (n=16)
.119

Control (n=24)
.134

p value
.240

.105
.191
.261
.323
.374
.422
.470
.499
.537
.577

.121
.222
.302
.377
.440
.478
.517
.565
.616
.664

.166
.179
.205
.191
.184
.306
.437
.283
.241
.245

1.40
1.01

1.40
1.02

.811
.640

Abbreviations: MSE, multiscale entropy; DFA, detrended fluctuation analysis
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Figure 14. Multiscale Entropy Analysis

Multiscale Entropy (~4 h)
0.80000
COVID + history

Sample entropy of SpO2

0.70000

Control

0.60000
0.50000
0.40000

0.30000
0.20000
0.10000
0.00000
1

2

3

4

5

6

7

8

9

10

Scale

Multiscale entropy analysis of sample entropy levels across 10 scales comparing complexity patterns between
individuals with previous COVID-19 infection (blue) and controls (orange) over four hour collection period.
Increased sample entropy with increasing scale is suggestive of complexity in both groups.

Figure 15. Detrended Fluctuation Analysis Sample for One Participant
2
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Sample detrended fluctuation analysis for one participant. Plotted calculation of root mean square of
fluctuation for short-term (scales 0.5 to 1.5) and long-term (scales 1.5 to 3.0) time scales. Linear shape of
graph suggests fractality in variability signaling.
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Figure 16. Network Physiology Analysis

Results from network physiology analysis between oxygen saturation, heart rate, respiratory rate and skin
temperature signals (nodes) for individuals with previous COVID-19 infection (left) and controls (right)
conducted for one hour of monitoring. Exchanges of transfer entropy (edges) represented by the direction of
information flow (orientation of arrow) and the magnitude of information flow (thickness of arrow).

Covariates of Infection
Inflammatory Salivary Biomarkers
Group differences in systemic inflammation biomarkers are displayed in Table 4. Systemic
inflammation measured with salivary cytokine biomarkers did not differ between our study
groups such that IL-8, IL-1ß, IL-6, and TNF-α did not significantly differ between COVID-19
individuals and controls (p>0.05). Differences in CRP levels were observed between groups
however this difference did not reach significance (p=.067). No group differences were
observed in systemic inflammation between recovering COVID-19 individuals and controls in
our subsample (p>0.05) (Supplementary Table 3).
No associations between inflammatory biomarkers and any measures of respiratory
function were observed in individuals with a history of COVID-19 infection. IL-6 was inversely
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associated with sedentary time (r=-.370, p=.049). For linear metrics of oxygen saturation
variability, average hourly change was inversely associated with TNF-α concentrations (r=-.497,
p=.025). IL-6 was associated with several nonlinear variability metrics, including short-term
DFA variability (α1) (r=-.593, p=.015), and MSE scales 5 (r=.426, p=.050) and 6 (r=.461,
p=.036).

Physical Activity and Sedentary Time
Participants in both groups met suggested physical activity guidelines for MVPA. No group
differences were observed for two of our accelerometer-derived physical activity measures such
that MVPA and sedentary time were not significantly different between COVID-19 and control
groups (p>0.05). All physical activity measures between groups are reported in Table 4. MVPA
was positively associated with FeNO levels (r=.473, p=.015). While no group differences were
observed, sedentary time was inversely associated with several pulmonary function parameters
including FEV1 (r=-.392, p=.040) and PEF (r=-.579, p=.003) in our overall COVID-19 group.
Additionally, no group differences were observed in physical activity measures within our
subsample (p>0.05) (Supplementary Table 3). Associations between sedentary time with PEF
(r=-.533, p=.050) remained in our subsample of COVID-19 individuals. No associations
between physical activity or sedentary time with linear or nonlinear oxygen saturation variability
were observed.

Infection Experience
Individuals in the COVID-19 group participated on average 94.0 ± 82.0 days since their positive
test, experiencing mild-to-moderate COVID-19 infection and an average of 6.0 ± 5.0 symptoms.
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Frequencies of specific symptoms experienced by those with a history of COVID-19 infection
are displayed in Supplementary Table 1. The most common symptoms experienced were fatigue
(79%), headache (75%) , nasal congestion (67%), and loss of smell (63%). Four participants
(16%) reported experiencing asymptomatic infection. No participants required hospitalization
for infection. Inverse associations were observed between FVC with both disease severity (r=.461, p=.012) and number of symptoms (r=-.404, p=.025). Additionally, disease severity was
negatively associated with FEV1 (r=-.365, p=.040). No associations were found with infection
experience and any linear or nonlinear oxygen saturation variability parameters. Number of days
since positive infection status was inversely correlated with sedentary time (r=.386, p=.042).
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Chapter 5: Discussion
This study primarily sought to assess the effect of COVID-19 infection on respiratory function in
young adults by comparing group differences in pulmonary function, airway inflammation, and
both linear and nonlinear metrics of oxygen saturation variability between individuals with a
history of COVID-19 infection and controls. Furthering our nonlinear analyses, we then
conducted a network physiology analysis to understand exchange of information between
regulatory components of the cardiorespiratory system by quantifying transfer entropy between
continuous SpO2, HR, respiratory rate and skin temperature signals. This was done to further
explore potential cardiorespiratory uncoupling between groups in our sample. Finally, we
explored the role of potential correlates of cardiorespiratory function including salivary
biomarkers of systemic inflammation, physical activity levels and sedentary time, and infection
experience as they relate to respiratory function and oxygen saturation variability in the COVID19 group. These findings indicate that there are no group differences in any of the primary
cardiorespiratory measures, suggesting that respiratory function and oxygen saturation variability
(linear and nonlinear) are similar between infection and control groups, in contrast to the study
hypothesis. Several associations amongst respiratory function, oxygen saturation variability,
systemic inflammation biomarkers, physical activity levels and infection experience were
observed and will be discussed below.
Taken together, the results of the current study show similar pulmonary function, airway
inflammation levels and oxygen saturation variability between recovering COVID-19 individuals
and controls with no history of infection. This suggests that mild-to-moderate COVID-19
infection does not have lasting effects on respiratory function and oxygen saturation variability
approximately three months into recovery. Similarly, results from network physiology analysis
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show similar levels of exchanges of transfer entropy amongst cardiorespiratory signals between
groups. These findings further suggest that cardiorespiratory integration and complexity of
control of SpO2 is not impaired following mild-to-moderate COVID-19 infection, indicating
there is no isolation within the cardiorespiratory system in those who have experienced COVID19 infection.

Group Differences in Respiratory Function
Pulmonary Function
The current study did not find any significant differences in any of our measures of respiratory
function; including pulmonary function, exhaled nitric oxide levels, linear and nonlinear
measurement of oxygen saturation variability, between individuals with a history of COVID-19
infection and healthy controls. Assessment of pulmonary function via spirometry included
measurement of FVC, FEV1, FEV1/FVC and PEF. The lack of group differences observed
between our study groups differs from findings of several previous studies, including accounts of
pulmonary function anomalies and diminished total lung capacity in 25% of subjects at three
months post-discharge from COVID-19 infection.6,12 In the former study, investigator Zhao
reported that approximately half of those exhibiting pulmonary function anomalies showed
reduced FVC or FEV1 values.12 Similarly, abnormally low FVC and FEV1 values were
published at 6 weeks follow-up to COVID-19 infection76 and at the time of patient discharge.6
An important distinction to make between the cohort of the current study and those
reported in these publications is the severity of COVID-19 infection experience and timeline of
measurement relative to infection. The cohort of the current study experienced mild-to-moderate
infection, was assessed on average three months into recovery, with no hospitalizations required.
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In contrast, the majority of literature evaluating individuals during recovery from infection is
reporting on follow-up assessments conducted post-hospitalization, encompassing the residual
effects of a far more severe tier of COVID-19 infection. However, one study identified the
frequency of pulmonary dysfunction at six months follow-up, revealing low FVC, FEV1, and
FEV1/FVC values in only 3%, 8% and 8% of the 89 patients included, respectively, however
these participants were also hospitalized during infection.147 A more representative study of our
cohort evaluating non-critical COVID-19 patients with mild-to-moderate infection reported no
differences in pulmonary function pre-to-post infection,148 aligning with our findings.
Furthermore, a larger scale study of 661 young adults (mean age 22.6 years) disclosed no
differences in mean change in FVC, FEV1 or FEV1/FVC between seronegative and seropositive
individuals.84 Abnormal pulmonary function has been deemed “rare” in children and adolescents
who did not experience severe infection.149 These studies evaluating younger cohorts and those
who had a more mild infection experience are more representative of our cohort and report
findings seemingly parallel to the current study.
Minimal studies have measured PEF in individuals with a history of COVID-19, however
one study reported normal mid-expiratory flow in conjunction with normal FVC and FEV1/FVC
values.85 Two accounts of direct measurement of PEF can be identified, one study yielding
normal PEF, FVC, FEV1, FEV1/FVC values in 379 patients four months post-infection (aligning
directly with the current study),150 and another an ongoing clinical trial yet to release their
findings.151 These findings taken together with the current study suggest that pulmonary
function is normal in young adults 3 months following mild-to-moderate COVID-19 infection.
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Exhaled Nitric Oxide
Our cohort exhibited slightly elevated exhaled nitric oxide (FeNO) levels, with average scores of
16.61 ppb (COVID+) and 20.03 ppb (Control), however these values were not significantly
different between groups. Prior to our investigation, few studies had considered FeNO
measurement as a means of evaluating post-COVID airway inflammation, as it was primarily
used in assessing individuals with asthma and other related respiratory conditions. FeNO may be
useful in a COVID_19 setting as several of the inflammatory molecules that compose the
cytokine storm characteristic to COVID-19 infection stimulate overproduction of NO in order to
contest constrictive changes to the airway80 and has previously been found to be associated with
changes in lung function.126 Higher FeNO values have been reported in critically ill patients
with pneumonia compared to those without.80 It is important to note, however, that the ailments
in this study were not COVID-19 related, although pneumonia is a common condition associated
with COVID-19 infection. The Yang et al. study appeared to be the first to use FeNO
measurement directly for evaluating respiratory function in COVID-19 patients, reporting
significantly higher values compared to healthy controls.82 Nevertheless, these values were
acquired during active infection, and do not give indication about FeNO measurement during
recovery.
As the novelty of the pandemic has decreased, more studies have now assessed FeNO in
recovering COVID-19 patients, with comparable results to the current study. A large scale study
of 661 young adults reported no differences in FeNO values between recovering COVID-19
individuals and controls, including 123 individuals with asthma in the analysis.84 Another study
that evaluated FeNO in a much smaller sample of 20 recovering COVID-19 individuals at 5
months post-infection revealed that 7 (39%) of their cohort had slightly elevated FeNO levels
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(25-50 ppb) indicating possible inflammation, but none reaching abnormal levels of over 50
ppb.85 Furthermore, a study measuring multiple-flow FeNO values reported no significant
differences in FeNO levels at a flow rate of 50 mL/s,86 the same flow rate used for data
collection with the NiOX VERO here. These findings suggest that FeNO measurement may be
plausible as a diagnostic tool during active COVID-19 infection, but more research is needed to
understand its significance during recovery. The findings of the current study indicate that
young adults with a history of COVID-19 infection have mild, but not abnormal airway
inflammation levels approximately three months into recovery from infection.

Oxygen Saturation Variability
This study employed both linear and nonlinear methods to quantify and compare oxygen
saturation variability between individuals with a history of COVID-19 infection and controls.
Assessing oxygen saturation variability using continuous monitoring accounts for the natural
fluctuations in SpO2 that spot check measurement cannot. This attempt to capture true
variability was conducted through analysis of a four-hour SpO2 signal, including basic variability
measures of mean, SD, RMS and average hourly change in conjunction with novel nonlinear
analyses of sample entropy, MSE and DFA. Further insight into cardiorespiratory system
control of SpO2 was provided via network physiology analysis of SpO2 as it relates to HR,
respiratory rate and skin temperature. While no group differences were observed for any linear
or nonlinear variability parameters during our continuous collection period, the results of these
analyses can be utilized to help define oxygen saturation variability and provide a baseline for
young adults both with and without histories of COVID-19 infection moving forward.
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A novel approach to SpO2 measurement, oxygen saturation variability, both linear and
nonlinear, has only been calculated in a handful of studies. Prior to the current work, oxygen
saturation variability had been quantified in specified populations and/or under unique
conditions, including infants,152 healthy adults,18 COPD patients,94 and healthy adults under a
graded hypoxic stimulus95 but had not been evaluated in a COVID setting. The literature
suggests that increased linear variability metrics associated with desaturation may be indicative
of disease, such as in the extended home monitoring of COPD patients.94 In contrast, decreased
nonlinear variability may indicate lower complexity and control system uncoupling associated
with aging and disease.18 It is important to note that although increased entropy/higher
complexity has been associated with tighter control system coupling during pathological or
environmental stimuli (desaturation or hypoxia)18,95 oxygen saturation variability is theoretically
more engaged during these conditions where homeostatic intervention by the cardiorespiratory
system is required. Despite this, however, oxygen saturation variability may still be decreased
compared to healthy counterparts due to injury or isolation to one or more of the regulatory
components involved in cardiorespiratory control. In summary, during a stimulus, it appears that
increased linear variability and decreased nonlinear variability distinguishes healthy and diseased
individuals.19,94,112,113
In the current study, no differences were observed in linear or nonlinear oxygen
saturation variability between our study groups. Our findings are supported by two recent
publications, suggesting that COVID-19 infection may not affect oxygen saturation homeostasis
in the same manner as we see in other respiratory conditions such as COPD. Mapelli et al.
reported no significant change in SpO2 at 7-12 days post-discharge (2-hour bout per day) but did
not compare these findings to a control population.153 Moreover, Banzi et al. conducted 8-day
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continuous SpO2 data collection during symptomatic COVID-19 infection, where no patient
experienced a 5% or greater decrease in saturation during monitoring.154
Network physiology analysis in the current work indicated that while there were
significant exchanges of information signaling between regulatory components of the
cardiorespiratory system, that the integrity of said control system is not compromised in those
with a history of COVID-19 infection when compared to their healthy counterparts.
Specifically, two additional studies have discussed similar system control as it relates to SpO 2
monitoring in COVID-19 patients. Mapelli et al. carried out extended at-home seven-day
continuous monitoring of identical cardiorespiratory parameters in recently discharged COVID19 patients, yielding similar results to the current study. No differences in any cardiorespiratory
parameters were observed from the day of hospital discharge to the last day of monitoring.153 It
is important to note, however, that these measures were not compared to a control group and the
average age of this cohort was 54 years, unlike the current sample. Desaturation during exercise
was observed in this same cohort, illustrating the cardiorespiratory dynamics discussed in
Michard et al.’s evaluation of continuous cardiorespiratory monitoring in individuals with
COVID-19 infection155 as hypothesized in the current study. While these multisignal
interactions were not different between our study groups, the results of our network analysis
echo that of previous studies,93,140 highlighting the exchange of physiological information across
the cardiorespiratory system. By successfully capturing this flow of information, we can
potentially identify points of isolation amongst regulatory components in the system during/after
not only COVID-19 infection, but also other pathological/environmental stimuli.93
When discussing the findings of the current work as they relate to the literature, the
timing of measurement and target populations should be considered. More specifically, the
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current cohort does not fall in a high-risk demographic, in terms of severity of infection and
potential age-related comorbidities. As previously highlighted regarding pulmonary function
performance, the present sample of healthy young adults experienced mild-to-moderate
infection, were assessed approximately three months post-infection, and required no
hospitalizations. Furthermore, in a risk assessment of COVID-19 patients, the presence of one or
more comorbidities such as diabetes or hypertension was found to be a strong risk factor for
hypoxia post-COVID infection.156 Because of our sample demographic, we may fail to see the
ongoing cardiorespiratory injury reported in other populations at similar points in recovery.
While no group differences were observed in any oxygen saturation variability measures,
we were able to gain important insight into oxygen saturation variability dynamics overall.
Similar to reports by Bhogal et al., SpO2 exhibited both fractality (self-similarity) and increased
long-term complexity in our overall sample.18 Furthermore, SpO2 displayed increased long-term
complexity when compared to short-term variations, denoted in our DFA, also echoing previous
investigations.18 As the demonstration of the feasibility and accessibility to similar
methodologies for home monitoring of SpO2 and associated measures increases in the COVID19 population,153–155 the current work functions to establish points of reference in regards to
oxygen saturation variability metrics, allowing for refinement in future methodical approaches
and comparison of observed patterns across populations. Our findings suggest that while
cardiorespiratory control of oxygen saturation is not impaired in young adults three months into
recovery from COVID-19 infection, there is significant information to be acquired within these
cardiorespiratory signals.
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Biobehavioral Correlates of Cardiorespiratory Function
Salivary biomarkers of inflammation, physical activity, sedentary time and infection experience
were explored in our COVID-19 group to assess potential correlates of cardiorespiratory
function. Although no group differences were observed in cardiorespiratory function, these
correlates were explored as potential mechanisms contributing to pulmonary injury, airway
inflammation or hindered oxygen saturation variability during COVID-19 recovery. Elevated
inflammatory profiles characteristic of increased disease severity may be responsible for injury
to the cardiorespiratory system, resulting in poor performance outcomes. Physical activity
metrics (MVPA and sedentary time), on the other hand, were chosen to assess the potential
protective effects of activity (or detrimental effects of lack thereof) on the cardiorespiratory
system and its functionality. When discussing physical activity metrics, an important distinction
to be made is the difference between physical activity and sedentary time, as well as the
physiological implications on cardiorespiratory function for each. While closely correlated with
one another, it is possible for an individual to be both physically active (meeting physical activity
guidelines) while still exhibiting substantial amounts of sedentary time. Additionally, these
constructs may offer individual insight into cardiorespiratory function as both exhibit
relationships with cardiorespiratory outcomes independent of the other.34,157–160 Therefore, we
distinguished between the two measures and assessed them as potential correlates of
cardiorespiratory function individually.
In the current sample, no associations between MVPA and pulmonary function were
observed. This lack of association could potentially be attributed to the activity levels of our
cohort, as our sample met suggested physical activity guidelines. While no associations were
found with pulmonary function, MVPA did exhibit a positive association with FeNO. Higher
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levels of physical activity have been found associated with increased FeNO levels in healthy
young adults.161 In contrast to the inflammatory response during infection, activity stimulates
endothelial production of eNOS, and releases nitric oxide into the airway, increasing NO
bioavailability and raising FeNO levels.161,162 Unlike MVPA, increased sedentary time exhibited
a relationship with respiratory decline, demonstrated by an inverse association with both FEV1
and PEF. Increased bouts of sedentary time have been reported to accelerate age-related decline
in lung function, and has previously demonstrated negative relationships with FEV1 and PEF
specifically.35,36 Reductions in cardiorespiratory function characterized by lower pulmonary
function may be attributed to a detraining effect at the lungs from lack of activity.34 Therefore,
while similar between our study groups, it is plausible that reductions in pulmonary function may
be due to increased bouts of sedentary time rather than the injuries related to acute COVID-19
infection.
Furthermore, sedentary time has previously been associated with elevated inflammatory
profiles, as the anti-inflammatory effects of increased activity are not seen. While we did not
observe any relationships between sedentary time and the pro-inflammatory cytokines (IL-8, IL1ß, TNF-α, CRP), we did note an inverse association between sedentary time and IL-6. In
contrast to other cytokines, IL-6 has functional roles outside of pro-inflammatory processes, and
increased concentrations have been documented in more active populations.163,164 More
specifically, muscle-derived IL-6 produced during activity has documented anti-inflammatory
effects, reported to combat pro-inflammatory cytokines such as its measured counterpart IL1ß.165 These findings suggest that sedentary time may contribute to an elevated inflammatory
profile due to a low production of anti-inflammatory IL-6.
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Regarding infection experience, disease severity exhibited a negative impact on
pulmonary function, noted by inverse relationships with both FVC and FEV1. Previous studies
assessing pulmonary function based on disease severity have yielded mixed findings. 6,148,150,166–
168

Interestingly, the relationship between disease severity and pulmonary function appears to be

more likely driven by more severe cases that include exacerbated inflammatory responses to
secondary injury such as COVID pneumonia, supplemental oxygen requirements or ARDS,
however this was not demonstrated in our recovering individuals. Not only did the current
sample report mild to moderate infection, but no associations between disease severity and any
inflammatory biomarkers were observed. Regardless, the reduction in pulmonary function in our
cohort may be due in part to the acute lung injury brought on by infection, independent of
inflammation levels. Taken together our findings suggest that both sedentary time and disease
severity may be indicative of respiratory decline in young adults recovering from COVID-19
infection. Finally, sedentary time may be a modifiable point of intervention for improving
pulmonary function during recovery in this population.

Limitations and Implications
While this study did provide a novel perspective into cardiorespiratory function of young adults
recovering from COVID-19 infection, it is not without limitations. Primarily, this study was
cross-sectional and correlational in design, and therefore cannot claim causality. Additionally,
due to the viral transmission risks posed to both participants and researchers when conducting
this study, much of the data collection was completed remotely, adding additional limitation for
achieving accurate and complete measurement of study variables. Furthermore, documentation
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of COVID-19 infection experience was self-reported up to six months post infection, and
therefore may not be entirely accurate.
Due to the novelty of the Equivital LifeMonitor device, there were several unforeseen
complications and extraneous variables that led to the failed sampling of several of our
participants, causing them to be excluded from our secondary analysis for oxygen saturation
variability metrics. Prior to its use in the current study, the Equivital was piloted in a small-scale
study, where it exhibited good reliability for eight-hour continuous measurement. However, due
to the remote functionality of our study, the set-up of the device was done over Zoom and
removal of device unsupervised, so neither could be physically conducted by a researcher.
Additionally, as has been mentioned in the few studies where the same device was used, the
quality of the data and successful collection by the device heavily relies on participant
cooperation with the device restrictions, as the pulse oximeter easily generates artifact during
higher activity levels and fidgeting with the device connection. Furthermore, our sample and
subsample were both predominantly white for our secondary analysis that decreased the
generalizability of our findings. However, it is important to note that there are no established
racial differences in oxygen saturation metrics per se, so it may not have contributed to the lack
of group differences observed in our cohort.
This study highlighted several measures that may be beneficial to managing recovery of
COVID-19 patients after infection. Future studies should continue to evaluate these components
of respiratory function in populations of varying infection severity and age. Additionally, pre-topost measurement of individuals who contract COVID-19 would allow for a more direct
comparison of changes in respiratory function, and repeated measurement throughout recovery
would be beneficial. More research is needed to quantify, understand, and compare oxygen
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saturation variability metrics and cardiorespiratory function in all populations, and may be
valuable in more severely impacted populations. The current work provides an important
baseline to be referenced moving forward when discussing oxygen saturation variability and
cardiorespiratory dynamics in any future bodies of work. As vaccination rates increase and
transmission risk decreases, more accurate and direct measurement of these populations should
become more plausible.

Conclusion
Respiratory function measured as pulmonary function, exhaled nitric oxide and oxygen
saturation variability does not differ between young adults who experienced mild-to-moderate
COVID-19 infection and healthy controls. Moreover, the significant exchange of information
(transfer entropy) between SpO2, HR, respiratory rate and skin temperature did not differ
between groups suggesting that both complexity and integrity (i.e., dynamic integration) within
the cardiorespiratory control system is not compromised during recovery from COVID-19.
Increased sedentary time and disease severity may have negative effects on pulmonary function
in this population. In conclusion, young adults who have experienced mild-to-moderate COVID19 infection do not appear to be at increased risk for future respiratory decline.
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Supplementary Table 1. Frequency of COVID-19 Symptomology
Symptom
Fever
Cough
Fatigue
Loss of Appetite
Shortness of Breath
Hyperventilation
Muscle Pain or Ache
Joint Pain or Ache
Sore Throat
Nasal Congestion or Runny Nose
Headache
Diarrehea
Nausea or Vomiting
Loss of Smell
Loss of Taste
Dehydration
Reduced Alertness
Purple Lesions on Hands or Feet
Persistent Chest Pain or Pressure
Confusion
Inability to Wake/Stay Awake
Blush Lips or Face
Other
Asymptomatic
Hospitalization

Number of Participants
10
12
19
11
9
1
13
9
12
16
18
3
4
15
11
5
6
0
3
3
3
0
3
4
0
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Supplementary Table 2. Subsample Participant Characteristics for Secondary Analysis
COVID+ (n=16)
26.6 ± 10.3

Age (years)
Sex (%)
Male
6 (37.5)
Female
10 (62.5)
Race/Ethnicity (%)
White
13 (81.3)
Hispanic
0 (0)
African American
1 (6.2)
Asian American
2 (12.5)
BMI (kg/m2)
23.69 ± 3.62
Body Fat (%)
22.47 ± 5.11
Questionnaire Data
Days Since Positive
120.88 ± 132.20
COVID Disease Severity
2.06 ± 0.85
COVID Symptoms
5.0 ± 5.0
Abbreviations: BMI, body mass index

Controls (n=24)
24.5 ± 7.1

23 (95.8)
0 (0)
1 (4.2)
0 (0)
25.45 ± 3.79
23.07 ± 4.69

p value
.733
.505
.191
.062
.389

-

-

10 (41.7)
14 (58.3)
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Supplementary Table 3. Subsample Group Differences in Respiratory Function, Systemic
Inflammation and Physical Activity
COVID+ (n=16)
Control (n=24)
p value Partial η2 Observed
Power
Respiratory Function
FVC, L (%)
4.28 ± 1.04 (105)
4.60 ± 1.11 (106)
.557
.021
.143
FEV1, L (%)
3.49 ± 0.77 (100)
3.71 ± 0.87 (99)
.672
.020
.136
FEV1/FVC (%)
85.06 ± 11.26 (99)
81.96 ± 8.43 (95)
.345
.025
.163
PEF, L/min (%)
363.75 ± 118.05 (88)
394.05 ± 141.85
.389
.013
.106
(86)
Nitric Oxide(ppb)
12.33 ± 4.44
21.21 ± 23.24
.123
.054
.294
Systemic
Inflammation
IL-8 (pg/mL)
711.44 ± 750.4
954.41 ± 1039.2
.641
.017
.122
IL-1ß (pg/mL)
104.87 ± 112.6
161.75 ± 174.9
.177
.034
.200
IL-6 (pg/mL)
3.95 ± 3.7
5.14 ± 4.8
.454
.019
.129
TNF-α (pg/mL)
4.53 ± 4.2
5.11 ± 5.8
.641
.003
.063
CRP (pg/mL)
942.86 ± 1395.3
483.37 ± 563.8
.159
.052
.285
Physical Activity
MVPA (min/day)
29.69 ± 17.71
34.85 ± 19.04
.500
.020
.121
Sedentary Time
710.62 ± 171.90
719.46 ± 170.78
.796
.001
.052
(min/day)
Abbreviations: FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; PEF,
peak expiratory flow; IL, interleukin; TNF, tumor necrosis factor; CRP, C-reactive protein;
MVPA, moderate to vigorous physical activity
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Supplementary Table 4. Participant Characteristics for Included v. Excluded Sample for
Secondary Analysis
Included (n=40)
Age (years)
25.4 ± 8.5
Sex (%)
Male
15 (37.5)
Female
25 (62.5)
Race/Ethnicity (%)
White
36 (90.0)
Hispanic
0 (0)
African American
2 (5.0)
Asian American
2 (5.0)
BMI (kg/m2)
24.75 ± 3.8
Body Fat (%)
22.83 ± 4.81
Questionnaire Data
Days Since Positive
121.0 ± 132.0
COVID Disease Severity
2.06 ± 0.85
COVID Symptoms
5.0 ± 5.0
*p value <0.05
Abbreviations: BMI, body mass index

Excluded (n=17)
21.5 ± 2.8

9 (52.9)
0 (0)
5 (29.4)
3 (17.6)
24.55 ± 2.86
22.07 ± 3.77

p value
.011*
.874
.007*
.875
.601

89.0 ± 62.0
2.50 ± 0.76
7.0 ± 4.0

1.00
.264
.214

6 (35.3)
11 (64.7)
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